US7238469B2 - Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis - Google Patents
Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis Download PDFInfo
- Publication number
- US7238469B2 US7238469B2 US10/177,930 US17793002A US7238469B2 US 7238469 B2 US7238469 B2 US 7238469B2 US 17793002 A US17793002 A US 17793002A US 7238469 B2 US7238469 B2 US 7238469B2
- Authority
- US
- United States
- Prior art keywords
- carbon monoxide
- donor
- cells
- organ
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 title claims abstract description 298
- 229910002091 carbon monoxide Inorganic materials 0.000 title claims abstract description 298
- 210000000056 organ Anatomy 0.000 title claims abstract description 151
- 230000006907 apoptotic process Effects 0.000 title description 117
- 238000000034 method Methods 0.000 claims abstract description 148
- 238000002054 transplantation Methods 0.000 claims abstract description 90
- 230000004083 survival effect Effects 0.000 claims abstract description 41
- 210000002216 heart Anatomy 0.000 claims description 69
- 239000008194 pharmaceutical composition Substances 0.000 claims description 61
- 238000011065 in-situ storage Methods 0.000 claims description 17
- 210000000496 pancreas Anatomy 0.000 claims description 17
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 210000004185 liver Anatomy 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 11
- 208000007204 Brain death Diseases 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 7
- 210000000813 small intestine Anatomy 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 abstract description 17
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 254
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 226
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 226
- 210000002889 endothelial cell Anatomy 0.000 description 211
- 150000001875 compounds Chemical class 0.000 description 174
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 142
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 129
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 129
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 129
- 210000001519 tissue Anatomy 0.000 description 93
- 239000007789 gas Substances 0.000 description 92
- 241000700159 Rattus Species 0.000 description 77
- 239000000203 mixture Substances 0.000 description 72
- 230000000694 effects Effects 0.000 description 61
- 108010005774 beta-Galactosidase Proteins 0.000 description 56
- 238000011282 treatment Methods 0.000 description 56
- 239000007788 liquid Substances 0.000 description 53
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 51
- 239000002609 medium Substances 0.000 description 51
- 230000002424 anti-apoptotic effect Effects 0.000 description 48
- 229930105110 Cyclosporin A Natural products 0.000 description 45
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 45
- 108010036949 Cyclosporine Proteins 0.000 description 45
- 229960001265 ciclosporin Drugs 0.000 description 45
- 101710172562 Cobra venom factor Proteins 0.000 description 44
- 238000002474 experimental method Methods 0.000 description 44
- 241000699666 Mus <mouse, genus> Species 0.000 description 43
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 42
- 102000005936 beta-Galactosidase Human genes 0.000 description 40
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 39
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 39
- 230000004913 activation Effects 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 33
- 230000001404 mediated effect Effects 0.000 description 32
- 239000013598 vector Substances 0.000 description 31
- 239000013604 expression vector Substances 0.000 description 30
- 230000006870 function Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 25
- 210000004102 animal cell Anatomy 0.000 description 24
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 23
- 230000002255 enzymatic effect Effects 0.000 description 23
- 210000004153 islets of langerhan Anatomy 0.000 description 23
- 229950003776 protoporphyrin Drugs 0.000 description 23
- 239000012298 atmosphere Substances 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 21
- 229910052742 iron Inorganic materials 0.000 description 21
- 238000001890 transfection Methods 0.000 description 21
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 150000003278 haem Chemical class 0.000 description 19
- 230000006698 induction Effects 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 230000000638 stimulation Effects 0.000 description 19
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 18
- 108010085238 Actins Proteins 0.000 description 18
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 206010012601 diabetes mellitus Diseases 0.000 description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 238000001262 western blot Methods 0.000 description 18
- 206010061216 Infarction Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000007574 infarction Effects 0.000 description 17
- 230000026731 phosphorylation Effects 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 206010052779 Transplant rejections Diseases 0.000 description 15
- 229910002092 carbon dioxide Inorganic materials 0.000 description 15
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 102000043136 MAP kinase family Human genes 0.000 description 14
- 108091054455 MAP kinase family Proteins 0.000 description 14
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 description 13
- 241001529936 Murinae Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 230000002018 overexpression Effects 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 108010078321 Guanylate Cyclase Proteins 0.000 description 12
- 102000014469 Guanylate cyclase Human genes 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- ZJRFCXHKYQVNFK-YEOHUATISA-M sodium 8-bromo-3',5'-cyclic GMP Chemical class [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br ZJRFCXHKYQVNFK-YEOHUATISA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- -1 control (pcDNA3) Proteins 0.000 description 11
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 11
- 239000012894 fetal calf serum Substances 0.000 description 11
- KYMXWWMCAPZBHQ-UHFFFAOYSA-N oxadiazolo[5,4-f]quinoxaline Chemical compound C1=CC2=NC=CN=C2C2=C1N=NO2 KYMXWWMCAPZBHQ-UHFFFAOYSA-N 0.000 description 11
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000012384 transportation and delivery Methods 0.000 description 11
- 102000008857 Ferritin Human genes 0.000 description 10
- 238000008416 Ferritin Methods 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 238000013467 fragmentation Methods 0.000 description 10
- 238000006062 fragmentation reaction Methods 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 230000002792 vascular Effects 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 101000976900 Homo sapiens Mitogen-activated protein kinase 14 Proteins 0.000 description 9
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 9
- 230000001640 apoptogenic effect Effects 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 9
- 229960005420 etoposide Drugs 0.000 description 9
- 230000006882 induction of apoptosis Effects 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 241000701161 unidentified adenovirus Species 0.000 description 9
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical group CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 9
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 8
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 7
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 238000011533 pre-incubation Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229950005371 zaprinast Drugs 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 108050000784 Ferritin Proteins 0.000 description 6
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 6
- 108010052014 Liberase Proteins 0.000 description 6
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000010412 perfusion Effects 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 5
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010035766 P-Selectin Proteins 0.000 description 5
- 102000008212 P-Selectin Human genes 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 230000009920 chelation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 238000011694 lewis rat Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000005241 right ventricle Anatomy 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 4
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 4
- 229940100513 Caspase 8 inhibitor Drugs 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 101001079613 Rattus norvegicus Heme oxygenase 1 Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 210000000709 aorta Anatomy 0.000 description 4
- 108010071933 benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 4
- 210000000013 bile duct Anatomy 0.000 description 4
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 108010057270 haemoferritin Proteins 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- SZXUTTGMFUSMCE-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyridine Chemical compound C1=CNC(C=2N=CC=CC=2)=N1 SZXUTTGMFUSMCE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 206010058490 Hyperoxia Diseases 0.000 description 3
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000003099 cyclic gmp dependent protein kinase inhibitor Substances 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003126 guanylate cyclase inhibitor Substances 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 229940025294 hemin Drugs 0.000 description 3
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000000222 hyperoxic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 206010022498 insulinoma Diseases 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 102000005869 Activating Transcription Factors Human genes 0.000 description 2
- 108010005254 Activating Transcription Factors Proteins 0.000 description 2
- 102000000546 Apoferritins Human genes 0.000 description 2
- 108010002084 Apoferritins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 101100328548 Rattus norvegicus C3 gene Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000011685 brown norway rat Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960001425 deferoxamine mesylate Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 108010031102 heme oxygenase-2 Proteins 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001479434 Agfa Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101100397594 Ancylostoma caninum JNK-1 gene Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 1
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 1
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 1
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 229940126560 MAPK inhibitor Drugs 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000702623 Minute virus of mice Species 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000756628 Mus musculus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101100381517 Mus musculus Bcl2 gene Proteins 0.000 description 1
- 101001079625 Mus musculus Heme oxygenase 1 Proteins 0.000 description 1
- 101000622138 Mus musculus P-selectin Proteins 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000034888 Needle issue Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000622139 Rattus norvegicus P-selectin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000002403 aortic endothelial cell Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- ZPGKBYMJBZKMAM-UHFFFAOYSA-I calcium;potassium;barium(2+);pentahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[K+].[Ca+2].[Ba+2] ZPGKBYMJBZKMAM-UHFFFAOYSA-I 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 102000053305 human HMOX1 Human genes 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the field of enhancing cell survival.
- Carbon monoxide (CO) gas is poisonous in high concentrations.
- CO Carbon monoxide
- It is now recognized as an important signaling molecule (Verma et al., Science 259:381–384, 1993). It has also been suggested that carbon monoxide acts as a neuronal messenger molecule in the brain (Id.) and as a neuro-endocrine modulator in the hypothalamus (Pozzoli et al., Endocrinology 735:2314–2317, 1994).
- nitric oxide (NO) carbon monoxide is a smooth muscle relaxant (Utz et al., Biochem Pharmacol.
- Islet cell transplantation is a viable treatment for the amelioration of type I diabetes (Lacy et al., Annu. Rev. Immunol., 2:183–98, 1984; Weir et al., J. Am. Optom. Assoc. 69:727–32, 2000; Berney et al., Langenbechs Arch. Surg. 385: 378–8, 2000; Shapiro et al., N Engl. J. Med., 343:230–8, 2000).
- PNF primary nonfunction
- transplanted organs can protect themselves from vascular injury leading to rejection through the expression of“protective genes” (see, e.g., Bach et al., Nature Med. 3:196–202 (1997); and Soares et al., Nat Med. 4:1073–1077, 1998).
- “protective genes” see, e.g., Bach et al., Nature Med. 3:196–202 (1997); and Soares et al., Nat Med. 4:1073–1077, 1998.
- heme oxygenase-1 heme oxygenase-1 (HO-1) catabolizes heme into biliverdin, free iron and CO (Tenhunen et al., Proc Natl Acad Sci USA 61:748–755, 1968).
- Endothelial cells lining blood vessels maintain blood flow, allowing the continuous traffic of plasma and cellular constituents between blood and parenchymal tissues.
- ECs must promote a certain level of vasorelaxation and inhibit leukocyte adhesion as well as coagulation and thrombosis.
- proinflammatory stimuli they become “activated” and promote vasoconstriction, leukocyte adhesion and activation, and coagulation and thrombosis.
- EC apoptosis is a prominent feature associated with acute and/or chronic inflammation such as it occurs during hyperoxia, endotoxic shock, arteriosclerosis, ischemia reperfusion injury, and acute or chronic graft rejection.
- the present invention is based, in part, on the observations that CO promotes the survival and/or function of organ, tissue, and individual cell transplants.
- the present invention provides a method of administering to a transplant donor a pharmaceutical composition containing carbon monoxide, obtaining an organ, tissue or cells from the donor, and transplanting the organ, tissue or cells into a recipient, where the amount of carbon monoxide administered to the donor is sufficient to enhance survival or function of the organ or tissue after transplantation into the recipient.
- the pharmaceutical composition can be administered to a live donor, to a brain-dead donor, or to the donor prior to and following brain death.
- the organ can be treated in situ in the donor and/or ex vivo with a pharmaceutical composition comprising carbon monoxide.
- the method can also or alternatively include the step of administering to the recipient a second pharmaceutical composition that includes carbon monoxide, before and/or during and/or after the step of transplanting the organ or tissue into the recipient.
- the organ or tissue can be any organ which can be transplanted, e.g., a liver, a kidney, a heart, a pancreas, a lung, small intestine, and/or skin, and the donor can be of a species different from that of the recipient, or the donor and the recipient can be of the same species.
- the donor and the recipient can both be non-human animals or humans.
- the donor can be a non-human animal such as pig, and the recipient can be a human.
- the invention provides a method of transplanting an organ, tissue or cells which includes providing an organ, tissue or cells of a donor, administering ex vivo or in situ to the organ, tissue or cells a pharmaceutical composition that includes carbon monoxide, and transplanting the organ or tissue into a recipient, wherein the amount of carbon monoxide is sufficient to enhance survival or function of the organ, tissue or cells in the recipient.
- the pharmaceutical composition is administered by perfusing the organ or tissue in situ while the organ or tissue is in the donor.
- the method can include the step of administering to the recipient a second pharmaceutical composition containing carbon monoxide before and/or during and/or after transplantation of the organ or tissue into the recipient.
- the invention provides a method of transplanting an organ, tissue or cells that includes the steps of providing an organ, tissue or cells of a donor, transplanting the organ, tissue or cells into a recipient, and before, and/or during, and/or after the step of transplanting the organ, tissue or cells into the recipient, administering to the recipient an amount of a pharmaceutical composition containing carbon monoxide sufficient to enhance survival and/or function of the transplanted organ, tissue or cells in the recipient.
- the pharmaceutical composition can be administered to the recipient within 0 to 20 days, e.g., within 1, 2, 4, 6, 8, 10, 12, 14, 18, or 20 days, after the organ has been transplanted into the recipient.
- the pharmaceutical composition is administered to the recipient at least once, e.g., multiple times or continuously, from the time beginning 21 days after the step of transplanting the organ or tissue into the recipient for as long as needed to ensure survival of the graft.
- the pharmaceutical composition can be administered to the recipient upon determination that the transplanted organ or tissue is undergoing or about to undergo rejection, e.g., chronic rejection or acute rejection.
- the method can further include the step of administering to the donor a second pharmaceutical composition containing carbon monoxide prior to obtaining the organ or tissue from the donor.
- the second pharmaceutical composition can be administered to a live donor or to a brain-dead donor.
- the method can include the step of administering to the organ a second pharmaceutical composition containing carbon monoxide in situ in the donor and/or ex vivo.
- the invention provides a method of enhancing the survival and/or function of a donor organ, tissue or cell which includes providing an organ, tissue or cell of a marginal donor and exposing the organ, tissue or cell to an amount of a pharmaceutical composition containing carbon monoxide sufficient to enhance the survival and/or function of the donor organ, tissue or cell.
- the invention provides a method of maintaining an animal cell in vitro that includes providing a vessel containing a pressurized gas that includes carbon monoxide gas, providing an isolated cell in vitro, wherein the cell is a primary cell or stem cell, releasing the pressurized gas from the vessel to form an atmosphere that includes carbon monoxide gas, and maintaining the animal cell in vitro in the presence of the atmosphere that includes carbon monoxide gas.
- the cell can then be transplanted into a recipient.
- the cell may be obtained from a donor that is not the recipient, or it may be obtained from the recipient.
- a carbon monoxide composition can be administered to the recipient prior to, and/or during, and/or after the transplantation step. This composition will typically be in the form of an inhaled gas.
- the animal cell is obtained from a donor by a method that includes administering a composition comprising carbon monoxide to the donor and obtaining the cell from a tissue of the donor.
- the invention also provides a method of maintaining an animal cell in vitro that includes providing a culture medium containing an effective amount of carbon monoxide, for example, at least 0.0001 g CO/100 g medium, and maintaining an isolated cell in the medium.
- the medium can contain, for example, at least 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, 0.0042, or 0.0044 g CO/100 g medium.
- the invention provides a method of enhancing survival of an animal cell after removal from a donor that includes administering to a live or brain-dead donor a pharmaceutical composition comprising carbon monoxide, and obtaining an isolated cell from the donor.
- the pharmaceutical composition can be, for example, supplied in the form of a pressurized gas suitable for inhalation by the donor.
- the method cam further include the step of maintaining the cell in vitro in the presence of a second composition containing carbon monoxide.
- the cell While in vitro the cell may be disposed in a liquid medium.
- the step of exposing the cell to the second carbon monoxide composition can be performed by providing a source of pressurized carbon monoxide gas and contacting the liquid medium with carbon monoxide gas released from the source.
- the liquid medium itself may also be provided as a carbon monoxide composition, i.e., with carbon monoxide dissolved therein.
- the invention provides a method of transplanting an animal cell that includes the steps of administering to a live or brain-dead donor a pharmaceutical composition comprising carbon monoxide, obtaining an isolated cell from the donor, and transplanting the cell into a recipient.
- the animal cell may be obtained from a donor that is not the recipient, or it may be obtained from the recipient.
- a carbon monoxide composition can be administered to the recipient prior to and/or during and/or after the transplantation step.
- the invention also provides a method of enhancing survival or function of an animal cell transplanted into a recipient that includes the steps of transplanting an animal cell into a recipient and before, during, and/or after the transplanting step, causing the recipient to inhale a sufficient amount of carbon monoxide gas to enhance survival or function of the transplanted cell in the recipient.
- the carbon monoxide gas can be supplied in the form of a vessel containing pressurized gas that includes carbon monoxide.
- the cell is maintained in vitro in an atmosphere comprising carbon monoxide prior to the transplant step.
- the animal cell can be maintained in a liquid medium that includes at least at least 0.0001 g carbon monoxide/100 g medium (e.g., at least about 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, 0.0042, or 0.0044 g CO/100 g medium).
- a liquid medium that includes at least at least 0.0001 g carbon monoxide/100 g medium (e.g., at least about 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, 0.00
- the method can optionally include the step of exposing the cell to a carbon monoxide composition ex vivo, prior to the transplanting step.
- the carbon monoxide gas can be administered to the recipient prior to and/or during and/or after the transplantation step.
- the animal cell may be obtained from a donor that is not the recipient, or it may be obtained from the recipient.
- a pharmaceutical composition comprising carbon monoxide can be administered to the donor prior to and/or during removal of the cell from the donor.
- the invention provides a method of improving survival of a transplanted cell in a recipient that includes administering to the recipient before and/or during and/or after transplantation of the cell into the recipient, an effective amount of a pharmaceutical composition comprising carbon monoxide gas.
- the survival effect may be enhanced by inducing the enzyme hemeoxygenase-1 (HO-1) in a donor or recipient, e.g., induced with heme, heavy metals, cytokines, hormones, nitric oxide endotoxins, UV irradiation, or glutathione depletors; or via heat shock.
- a donor or recipient e.g., induced with heme, heavy metals, cytokines, hormones, nitric oxide endotoxins, UV irradiation, or glutathione depletors
- heat shock hemeoxygenase-1
- the enzyme can be induced in the organ, tissue, or cells ex vivo, prior to transplantation into the recipient.
- the invention further provides an article of manufacture that includes a vessel containing pressurized gas, that contains at least 0.001 ppm, e.g., at least about 1, 10, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 5000, 10,000, 100,000, 200,000, 300,000, 400,000, 500,000, and up to 1,000,000 ppm carbon monoxide, and a label describing use of the gas to enhance survival of isolated animal cells, tissues, or islets before, during or after transplantation of the cells, tissues, or islets into a patient.
- a vessel containing pressurized gas that contains at least 0.001 ppm, e.g., at least about 1, 10, 50, 100, 150, 200, 250, 300, 500, 1000, 2000, 5000, 10,000, 100,000, 200,000, 300,000, 400,000, 500,000, and up to 1,000,000 ppm carbon monoxide, and a label describing use of the gas to enhance survival of isolated animal cells, tissues, or islets before, during or after transplantation of the cells
- a sterile cell medium that includes nutrients suitable for maintaining an animal cell in culture and at least about 0.0001 g carbon monoxide/100 g medium, e.g., at least 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, 0.0042, or 0.0044 g CO/100 g medium. It may also contain animal cells.
- a method of maintaining an animal cell in vitro and then transplanting it includes the steps of providing a vessel containing pressurized gas containing carbon monoxide gas; providing an isolated animal cell in vitro, wherein the cell is disposed in a medium that contains dissolved carbon monoxide; releasing the pressurized gas from the vessel to form an atmosphere comprising carbon monoxide gas; maintaining the cell in the presence of the atmosphere; and transplanting the cell into a recipient.
- the cell can be any cell.
- the cell can be an animal cell such as a primary, secondary, or cell line cell.
- the cell can be part of a pancreatic islet, e.g., a é-cell.
- the cell can also be, e.g., a liver cell, a fibroblast, a bone marrow cell, a neuronal cell, a mocyte, a lymphocyte, or a stem cell.
- the tissue is preferably not blood and contains little if any whole blood, and the cells are preferably not red blood cells and are not accompanied by a significant number of red blood cells.
- FIG. 1A is a bar graph that illustrates the effect of treatment of ⁇ TC3 cells with increasing concentrations of TNF- ⁇ .
- FIG. 1B is a graphical representation illustrating a FACScanTM analysis of DNA fragmentation in ⁇ TC3 cells following treatment with TNF- ⁇ .
- FIG. 1C is a bar graph that illustrates the effect of co-transfecting ⁇ TC3 with a ⁇ -gal expressing vector (pcDNA3/ ⁇ -gal) plus control (pcDNA3), and treatment with either the caspase-3 inhibitor Z-DEVD-FMK (C3-i) or the caspase-8 inhibitor IETD-CHO (C8-i).
- Gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ for 24 hours. Results shown are the mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- FIG. 2A is a bar graph showing that exogenous carbon monoxide can substitute for HO-1 (hemeoxygenase-1) when HO-1 activity is blocked. Gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ or etoposide or subjected to serum deprivation. Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- FIG. 2B is a graphical representation of a FACScanTM analysis of DNA fragmentation in ⁇ TC3 cells following 24 hour treatment with carbon monoxide after treatment with TNF- ⁇ .
- FIG. 2C is a bar graph illustrating that exogenous carbon monoxide protects ⁇ -cells from apoptosis in the absence of HO-1.
- ⁇ TC3 cells were transfected with ⁇ -gal expressing vectors and were exposed to exogenous carbon monoxide. Gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ or etoposide or subjected to serum deprivation as indicated. Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- FIG. 3 is a DNA fragmentation analysis by FACScanTM that indicates that exogenous carbon monoxide protects murine islets of Langerhans from apoptosis.
- CHX cycloheximide.
- FIG. 4A is a bar graph illustrating that the anti-apoptotic effect of exogenous carbon monoxide is mediated by guanylate cyclase activation.
- ODQ guanylyl cyclase inhibitor ODQ.
- FIG. 4B is a bar graph illustrating that cGMP analogue can substitute for carbon monoxide in protecting cells from apoptosis.
- 8-Br-cGMP cGMP analogue 8-Br-cGMP.
- FIG. 4C is a bar graph illustrating that cGMP-dependent protein kinases (cGK) mediate the anti-apoptotic effect of carbon monoxide.
- ⁇ TC3 cells were co-transfected with ⁇ -gal expressing vector.
- gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ . Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- KT protein kinase G inhibitor KT5823.
- FIG. 5A is a bar graph showing that one hour of carbon monoxide exposure is sufficient to prevent apoptosis.
- FIG. 5B is a bar graph showing that carbon monoxide protects ⁇ -cells after induction of apoptosis.
- FIG. 5C is a bar graph showing that preincubation with carbon monoxide prevents ⁇ -cell apoptosis.
- gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ . Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- FIG. 6A is a line graph indicating that exposure of murine islets to carbon monoxide improves survival and function following transplantation.
- FIG. 7 is a bar graph that illustrates expression of HO-1 in mouse hearts transplanted into CVF plus CsA-treated rats.
- Mouse hearts were transplanted into rats treated at the time of transplantation with cobra venom factor (CVF) plus daily treatments after transplantation with cyclosporin A (CsA).
- CVF cobra venom factor
- CsA cyclosporin A
- Expression of HO-1 and ⁇ -actin mRNA were detected by RT-PCR.
- the symbol ⁇ / ⁇ indicates RNA from HO-1 ⁇ / ⁇ mouse hearts used as a negative control. Histograms represent relative level of HO-1 mRNA expression normalized for expression of mactin mRNA.
- FIG. 8 is a set of bar graphs illustrating that SnPPIX inhibits HO-1 enzymatic activity in vivo.
- Mouse hearts were transplanted into untreated rats (II) or into rats treated with, CVF and CsA (III) plus FePPIX (IV) or SnPPIX (V).
- Total HO activity in donor and recipient hearts was measured 2 days after transplantation and compared with basal HO activity in normal mouse and rat hearts, respectively (I). Results shown are the mean ⁇ standard deviation (SD) of three animals analyzed for each treatment.
- SD standard deviation
- FIG. 9 is a set of line graphs illustrating that SnPPIX and FePPIX do not interfere with the generation of anti-graft antibodies (Abs).
- FIG. 10A is a set of bar graphs illustrating that exogenous CO does not affect the ability of SnPPIX to suppress HO-1 enzymatic activity.
- Mouse hearts were transplanted into rats treated with CVF plus CsA plus SnPPIX (II) or SNPPIX and CO (III).
- Total HO activity was measured in donors' and recipients' hearts as well as in recipients' livers 2 days after transplantation.
- HO activity in different specimens was compared with basal HO activity in normal mouse hearts (I), rat hearts (I), or livers (I), according to the sample analyzed. Results shown are the mean ⁇ SD of three animals analyzed for each treatment. Statistical analyses were conducted by using unpaired Welsh t test.
- FIG. 10B is a bar graph that illustrates that exogenous CO does not affect the ability of SnPPIX to suppress HO-1 activity.
- FIG. 11 is a line graph illustrating that up-regulation of HO-1 in endothelial cells inhibits platelet activation.
- Mouse 2F–2B endothelial cells were left untreated (NT) or were treated with CoPPIX (50 ⁇ M, 16 h) to up-regulate HO-1 activity, SnPPIX to suppress HO-1 activity (50 ⁇ M, 16 h), or CoPPIX (50 ⁇ M, 12 h) plus SnPPIX (50 ⁇ M, 4 h) to control for the specificity of CoPPIX in up-regulating HO-1 activity.
- Rat platelets were isolated, overlaid onto the mouse endothelial cells for 5 min, and tested for aggregation after stimulation with 2 ⁇ M of adenosine diphosphate (ADP).
- ADP adenosine diphosphate
- FIG. 12 is a bar graph illustrating that carbon monoxide suppresses endothelial cell apoptosis. Gray histograms represent cells treated with Act.D alone and black histograms represent cells treated with Act.D plus TNF- ⁇ . Where indicated, endothelial cells were treated with SnPPIX (50 ⁇ M) and exposed to exogenous CO (10,000 parts per million (ppm)).
- GFP green fluorescent protein
- FIG. 13D is a set of bar graphs illustrating that overexpression of HO-1 prevents EC apoptosis induced by proapoptotic stimuli such as etoposide or serum deprivation.
- Gray bars represent untreated ECs and black bars represent ECs treated with etoposide (200 ⁇ M, 8 h) or subjected to serum deprivation (0.1% FCS for 24 h).
- FIG. 14A is a bar graph illustrating that the antiapoptotic effect of HO-1 is dose dependent. Results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- FIG. 15A is a set of bar graphs illustrating that the antiapoptotic effect of HO-1 is dependent on HO enzymatic activity.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 15B is a bar graph illustrating that protoporphyrins alone have no detectable effect on EC viability.
- FIG. 16 is a set of bar graphs illustrating that scavenging of CO by hemoglobin (Hb) suppresses the antiapoptotic effect of HO-1.
- pcDNA3 ⁇ -galactosidase plus control expression vector
- HO-1 ⁇ -galactosidase plus ⁇ -actin/HO-1 expression vector
- Bcl-2 ⁇ -galactosidase plus bcl-2 expression vector.
- ECs were either left untreated (0) or were treated with increasing concentrations of Hb.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 17A is a bar graph illustrating that exogenously administered CO suppresses TNF- ⁇ -mediated apoptosis in ECs. Gray bars represent ECs treated with Act.D. Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 17B is a bar graph illustrating that exogenously administered CO (10,000 ppm) suppresses TNF- ⁇ -mediated apoptosis in ECs in the presence of tin protoporphyrin, but not in the presence of Hb.
- FIG. 18 is a bar graph and diagram illustrating that ECs that express HO-1 suppress apoptosis of ECs that do not express HO-1.
- ECs were transfected with control (pcDNA3; I and II) or HO-1 (III) expression vectors. ECs were then transfected with ⁇ -galactosidase (I and II) or with ⁇ -galactosidase plus HO-1 (III). Gray bars represent ECs treated with Act.D. Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 19A is a bar graph illustrating that upregulation of endogenous HO-1 expression by heme inhibits EC apoptosis via CO.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 19B is a bar graph illustrating that heme is unable to suppress EC apoptosis when CO is scavenged by Hb.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 20A is a bar graph illustrating that iron chelation by deferoxamine mesylate (DFO) suppresses EC apoptosis.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 20B is a bar graph and grid illustrating that DFO suppresses EC apoptosis in the presence of tin protoporphyrin.
- (+) HO-1 transfected cells treated with tin protoporphyrin and/or exogenous DFO.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 20C is a bar graph and grid illustrating that DFO suppresses EC apoptosis in the presence of heme.
- (+) HO-1 transfected cells treated with tin protoporphyrin and/or exogenous DFO.
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 21 is a bar graph and grid illustrating that iron chelation and CO have additive effects in suppressing EC apoptosis.
- (+) HO-1 transfected cells treated with tin protoporphyrin and/or exogenous DFO (100 ⁇ M) and/or CO (250 ppm).
- Gray bars represent ECs treated with Act.D.
- Black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 22A is a bar graph illustrating that the antiapoptotic effect of HO-1 does not involve a cGMP-dependent pathway.
- HO-1-transfected cells were exposed to increasing doses of the guanylcyclase inhibitor ODQ. Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 22B is a picture of a Western blot illustrating that expression of HO-1 in ECs did not result in a detectable increase of vasodilatator-stimulated phosphoprotein (VASP) phosphorylation.
- VASP vasodilatator-stimulated phosphoprotein
- FIG. 22C is a bar graph that illustrates that the cGMP analogue 8-Br-cGMP does not suppress EC apoptosis. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 22D is a picture of a Western blot illustrating that exposure of ECs to 8-Br-cGMP results in a detectable increase of VASP phosphorylation.
- N.T. not treated;
- pcDNA3 cells transfected with pcDNA3;
- HO-1 cells transfected with HO-1.
- FIG. 23A are pictures of Western blots illustrating that HO-1 increases TNF- ⁇ -mediated activation of p38 MAPK in ECs.
- FIG. 23B is a line graph illustrating the quantification of phosphorylation of several MAPKs. The results are presented as fold induction in arbitrary units (A.U.), compared with time 0, before TNF- ⁇ stimulation.
- FIG. 24A is a bar graph illustrating that HO-1 modulates p38 MAPK activation in ECs.
- BAECs were either nontransduced (NT) or transduced with a ⁇ -galactosidase ( ⁇ gal.) or HO-1 recombinant adenovirus, and were left untreated ( ⁇ ) or treated (+) with TNF- ⁇ (10 ng/ml for 15 min). Results are presented as fold induction of MAPK activation by TNF- ⁇ in arbitrary units (A.U.), compared with time 0, before TNF- ⁇ stimulation.
- FIG. 24B is a bar graph illustrating that CO modulates p38 MAPK activation in ECs.
- BAECs were stimulated (+) or not ( ⁇ ) by TNF- ⁇ (10 ng/ml, 30 min) in the presence or absence of CO (10,000 ppm). Results are presented as fold induction of MAPK activation by TNF- ⁇ in arbitrary units (A.U.), compared with time 0, before TNF- ⁇ stimulation.
- FIG. 25A is a bar graph illustrating that the antiapoptotic action of HO-1 is suppressed when p38 MAPK activation is blocked with pyridinyl imidazol SB203580 (10–20 ⁇ M), a specific inhibitor of p38 MAPK.
- ECs were cotransfected with ⁇ -galactosidase, control (pcDNA3), or HO-1 ( ⁇ -actin/HO-1) expression vectors. Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 25B is a line graph illustrating that activation of p38 MAPK by TNF- ⁇ was significantly inhibited (85–95%) in ECs exposed to SB203580 (5–20 ⁇ M), compared with control ECs stimulated by TNF- ⁇ in the absence of SB203580.
- BAECs were transfected with a control (pcDNA3) vector and stimulated with TNF- ⁇ in the presence ( ⁇ ) or absence ( ⁇ ) of the p38 kinase inhibitor SB203580 (20 ⁇ M).
- MAPK phosphorylation was monitored by Western blot (0, 5, 15, 30, 60, and 120 min after TNF- ⁇ stimulation).
- FIG. 25C is a bar graph illustrating that overexpression of a dominant negative mutant of p38/CSBP1 suppressed the ability of HO-1 to prevent EC apoptosis.
- ECs were cotransfected with ⁇ -galactosidase, control, HO-1 ( ⁇ -actin/HO-1), and where indicated with a phosphorylation-deficient p38/CSBP1 dominant negative mutant (DNM) expression vector. The values indicate the amount of vector used, in nanograms of DNA per 300 ⁇ 10 3 cells. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- FIG. 25D is a picture of a Western blot illustrating that the inhibitory effect was dose dependent in that increasing amounts of the p38/CSBP1 dominant negative mutant were more efficient in suppressing the antiapoptotic action of HO-1. No Tr., nontransfected ECs.
- carbon monoxide (or “CO”) as used herein describes molecular carbon monoxide in its gaseous state, compressed into liquid form, or dissolved in aqueous solution.
- carbon monoxide composition and “pharmaceutical composition comprising carbon monoxide” are used throughout the specification to describe a gaseous, liquid, solid, or semi-solid composition containing carbon monoxide that can be administered to a donor patient, cadaver, or animal; to an organ; or to a portion of an organ, e.g., tissues of the organ, or individual cell(s) that make up the organ, e.g., neurons, hepatocytes, myocytes, islets, or islet cells such as a pancreatic ⁇ -cell.
- the skilled practitioner will recognize which form of the pharmaceutical composition, e.g., gaseous, liquid, or both gaseous and liquid forms, is preferred for a given application.
- an effective amount and “effective to treat,” as used herein, refer to an amount or concentration of carbon monoxide utilized for period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome.
- Effective amounts of carbon monoxide for use in the present invention include, for example, amounts that are effective for enhancing survival and/or improving function of organs or cells in vivo and/or in vitro.
- an effective amount of carbon monoxide is that amount administered to the transplant donor and/or recipient sufficient to enhance survival of the cell or mass of cells, e.g.
- an effective amount of carbon monoxide is that amount with which the cells are incubated or stored in order to enhance preservation of the cells and/or to reduce cell loss, e.g., loss via apoptosis, and/or to enhance function.
- an effective amount of carbon monoxide is that amount administered to the transplant donor and/or recipient sufficient to enhance survival of the organ, tissue or cells of interest, e.g., to reduce loss of cells from which the organ or tissue is composed, and/or to improve functional performance of an organ.
- an effective amount of carbon monoxide is an amount sufficient to enhance survival and/or function of the organ or tissues.
- the term “inhibiting” includes delaying the onset of, reducing, preventing, or alleviating a biological process, e.g., apoptosis.
- effective amounts of carbon monoxide generally fall within the range of about 0.0000001% to about 0.3% by weight, e.g., 0.0001% to about 0.25% by weight, preferably at least about 0.001%, e.g., at least 0.005%, 0.010%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight of carbon monoxide.
- Preferred ranges of carbon monoxide include 0.001% to about 0.24%, about 0.005% to about 0.22%, about 0.01% to about 0.20%, and about 0.01% to about 0.1% by weight.
- effective amounts generally fall within the range of about 0.0001 to about 0.0044 g CO/100 g liquid, e.g., at least 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, or 0.0042 g CO/100 g aqueous solution.
- Preferred ranges include, e.g., about 0.0010 to about 0.0030 g CO/100 g liquid, about 0.0015 to about 0.0026 g CO/100 g liquid, or about 0.0018 to about 0.0024 g CO/100 g liquid. A skilled practitioner will appreciate that amounts outside of these ranges may be used, depending upon the application.
- patient is used throughout the specification to describe an animal, human or non-human, to whom treatment according to the methods of the present invention is provided.
- Veterinary applications are clearly anticipated by the present invention.
- the term includes but is not limited to birds, reptiles, amphibians, and mammals, e.g., humans, other primates, pigs, rodents such as mice and rats, rabbits, guinea pigs, hamsters, cows, horses, cats, dogs, sheep and goats.
- donor or “donor patient” as used herein refers to an animal (human or non-human) from whom an organ, tissue or individual cells can be obtained for the purposes of storage and/or transplantation to a recipient patient.
- recipient or “recipient patient” refers to an animal (human or non-human) into which an organ, tissue, mass of cells or individual cells can be transferred.
- diabetes is a general term to describe diabetic disorders as they are recognized in the art, e.g., Diabetes Mellitus. Diabetes Mellitus is characterized by an inability to regulate blood glucose levels. The two most prevalent types of diabetes are known as Type I and Type II diabetes. In Type I, or insulin-dependent diabetes (IDDM), the pancreas makes little or no insulin because the insulin-producing beta cells have been destroyed. In Type II, or noninsulin-dependent diabetes (NIDDM), the pancreas makes some insulin but the insulin is not effective.
- IDDM insulin-dependent diabetes
- NIDDM noninsulin-dependent diabetes
- diabetes also encompasses the myriad secondary disorders caused by diabetes, both acute and chronic, e.g., diabetic complications, e.g., hypoglycemia and hyperglycemia, retinopathy, angiopathy, neuropathy, and nephropathy.
- diabetic complications e.g., hypoglycemia and hyperglycemia, retinopathy, angiopathy, neuropathy, and nephropathy.
- cell(s) or “animal cell(s)” as used herein refers to any type of animal cells, including animal cells suitable for transplantation.
- the cells are typically primary cells obtained from an animal donor, but can be secondary cells or even cells of an established cell line. They are optionally transfected ex vivo with an expression vector that alters their function in some way.
- the cells include, but are not limited to, e.g., islet cells, e.g., cells which are part of a pancreatic islet, and liver cells, fibroblasts, bone marrow cells, myocytes, and stem cells, and cells of the central nervous system, including the spinal cord.
- islet cell(s) is used throughout the specification as a general term to describe the clumps of cells within the pancreas known as islets, e.g., islets of Langerhans. Islets of Langerhans contain several cell types that include, e.g., ⁇ -cells (which make insulin), ⁇ -cells (which produce glucagons), ⁇ -cells (which make somatostatin), F cells (which produce pancreatic polypeptide), enterochromaffin cells (which produce serotonin), PP cells and D1 cells.
- stem cell is an art recognized term that refers to cells having the ability to divide for indefinite periods in culture and to give rise to specialized cells. Included within this term are, for example, totipotent, pluripotent, multipotent, and unipotent stem cells, e.g., neuronal, liver, muscle, and hematopoietic stem cells.
- isolated cell is meant that the cell is removed from the tissue or organ in which it (or its predecessor) naturally occurs.
- a cell can be just partially purified from its natural milieu and be deemed “isolated.”
- an intact islet of Langerhans is considered to be made up of “isolated” cells, once the islet is removed from a pancreas and can be physically separated from other islets.
- the cells of an intact organ such as a kidney or heart or a partial organ such as a piece of a blood vessel are not considered to be “isolated cells” while still part of the organ.
- organs is used throughout the specification as a general term to describe any anatomical part or member having a specific function in the animal. Further included within the meaning of this term are substantial portions of organs, e.g., cohesive tissues obtained from an organ. Such organs include but are not limited to kidney, liver, heart, intestine, e.g., large or small intestine, pancreas, and lungs. Further included in this definition are bones and blood vessels, e.g., aortic transplants.
- transplantation is used throughout the specification as a general term to describe the process of implanting an organ, tissue, mass of cells, or individual cells into a patient.
- the term “transplantation” is defined in the art as the transfer of living tissues or cells from a donor to a recipient, with the intention of maintaining the functional integrity of the transplanted tissue or cells in the recipient (see, e.g., The Merck Manual , Berkow, Fletcher, and Beers, Eds., Merck Research Laboratories, Rahway, N.J., 1992).
- cell transplantation is used throughout the specification as a general term to describe the process of transferring at least one cell, e.g., an islet cell(s), to a patient.
- transplantation can be performed by removing the ⁇ -cells (or intact islets) from a donor's pancreas and putting them into a recipient patient whose pancreas cannot produce sufficient insulin.
- the terms include all categories of transplants known in the art, except blood transfusions.
- Transplants are categorized by site and genetic relationship between donor and recipient. The term includes, e.g., autotransplantation (removal and transfer of cells or tissue from one location on a patient to the same or another location on the same patient), allotransplantation (transplantation between members of the same species), and xenotransplantation (transplantations between members of different species).
- organ rejection is art-recognized, and are used throughout the specification as a general term to describe the process of rejection of an organ, tissues, or cells in a recipient. Included within the definition are, for example, three main patterns of rejection that are usually identified in clinical practice: hyperacute rejection, acute rejection, and chronic rejection (see, e.g., Oxford Textbook of Surgery , Morris and Malt, Eds., Oxford University Press, 1994).
- a marginal donor can include a donor that is older than 50 years old, or that is afflicted with a chronic disease that may affect graft function, e.g., diabetes, HTA and alcohol intake.
- a marginal organ is, for example, (1) an organ from such a donor, or (2) an organ that has experienced prolonged warm or cold ischemia times, or (3) an organ that presents with anatomical abnormalities (e.g., small and multiple vessels, e.g., in the kidney) that can render the vascular anastomosis difficult, or with evidence of atherosclerostic plaques on graft vessels.
- anatomical abnormalities e.g., small and multiple vessels, e.g., in the kidney
- a carbon monoxide composition may be a gaseous carbon monoxide composition.
- Compressed or pressurized gas useful in the methods of the invention can be obtained from any commercial source, and in any type of vessel appropriate for storing compressed gas.
- compressed or pressurized gases can be obtained from any source that supplies compressed gases, such as oxygen, for medical use.
- the pressurized gas including carbon monoxide used in the methods of the present invention can be provided such that all gases of the desired final composition (e.g., CO and O 2 , and optionally N 2 , He, and/or CO 2 ) are mixed together in the same vessel. If desired, the methods of the present invention can be performed using multiple vessels containing individual gases.
- a single vessel can be provided that contains carbon monoxide, with or without other gases, the contents of which can be optionally mixed with room air or with the contents of other vessels, e.g., vessels containing oxygen, nitrogen, carbon dioxide, compressed air, or any other suitable gas or mixtures thereof.
- Gaseous compositions administered to a patient according to the present invention typically contain 0% to about 79% by weight nitrogen, about 21% to about 100% by weight oxygen and about 0.0000001% to about 0.3% by weight (corresponding to about 0.001 ppm (i.e., 1 ppb) to about 3,000 ppm) carbon monoxide.
- the amount of nitrogen in the gaseous composition is about 79% by weight
- the amount of oxygen is about 21% by weight
- the amount of carbon monoxide is about 0.0001% to about 0.25% by weight.
- the amount of carbon monoxide is preferably at least about 0.001%, e.g., at least about 0.005%, 0.01%, 0.02%, 0.025%, 0.03%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.15%, 0.20%, 0.22%, or 0.24% by weight.
- Preferred ranges of carbon monoxide include about 0.001% to about 0.24%, about 0.005% to about 0.22%, about 0.010% to about 0.20%, and about 0.015% to about 0.1% by weight.
- gaseous carbon monoxide compositions having concentrations of carbon monoxide greater than 0.3% may be used for short periods (e.g., one or a few breaths), depending upon the application. They are particularly useful for ex vivo applications, where carbon monoxide poisoning is not a risk.
- the gas can contain carbon dioxide as well, to help maintain the pH of the medium.
- the carbon dioxide can be present at, for example, 1% to 10%, commonly 5%, by weight.
- a gaseous carbon monoxide composition may be used to create an atmosphere that comprises carbon monoxide gas.
- An atmosphere that includes appropriate levels of carbon monoxide gas can be created, for example, by providing a vessel containing a pressurized gas comprising carbon monoxide gas, and releasing the pressurized gas from the vessel into a chamber or space to form an atmosphere that includes the carbon monoxide gas inside the chamber or space.
- the gases can be released into an apparatus that culminates in a breathing mask or breathing tube, thereby creating an atmosphere comprising carbon monoxide gas in the breathing mask or breathing tube and ensuring the patient is the only person in the room exposed to significant levels of carbon monoxide.
- Carbon monoxide levels in an atmosphere or a ventilation circuit can be measured or monitored using any method known in the art. Such methods include electrochemical detection, gas chromatography, radioisotope counting, infrared absorption, colorimetry, and electrochemical methods based on selective membranes (see, e.g., Sunderman et al., Clin. Chem. 28:2026–2032, 1982; Ingi et al., Neuron 16:835–842, 1996). Sub-parts per million carbon monoxide levels can be detected by, e.g., gas chromatography and radioisotope counting.
- carbon monoxide levels in the sub-ppm range can be measured in biological tissue by a midinfrared gas sensor (see, e.g., Morimoto et al., Am. J. Physiol. Heart. Circ. Physiol 280:H482–H488, 2001). Carbon monoxide sensors and gas detection devices are widely available from many commercial sources.
- a carbon monoxide composition may also be a liquid carbon monoxide composition.
- a liquid can be made into a carbon monoxide composition by any method known in the art for causing gases to become dissolved in liquids.
- the liquid can be placed in a so-called “CO 2 incubator” and exposed to a continuous flow of carbon monoxide until a desired concentration of carbon monoxide is reached in the liquid.
- carbon monoxide gas can be “bubbled” directly into the liquid until the desired concentration of carbon monoxide in the liquid is reached. The amount of carbon monoxide that can be dissolved in a given aqueous solution increases with decreasing temperature.
- an appropriate liquid may be passed through tubing that allows gas diffusion, where the tubing runs through an atmosphere comprising carbon monoxide (e.g., utilizing a device such as an extracorporeal membrane oxygenator).
- the carbon monoxide diffuses into the liquid to create a liquid carbon monoxide composition.
- the liquid can be any liquid known to those of skill in the art to be suitable for administration to patients (see, for example, Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994) or for maintaining organs, tissues or cells ex vivo.
- the liquid will be an aqueous solution.
- solutions include Phosphate Buffered Saline (PBS), CelsiorTM solution, PerfadexTM solution, Collins solution, citrate solution, and University of Wisconsin (UW) solution (Oxford Textbook of Surgery, Morris and Malt, Eds., Oxford University Press, 1994).
- the liquid compositions can include carbon monoxide at concentrations in the range of about 0.0001 to about 0.0044 g CO/100 g liquid, e.g., at least 0.0002, 0.0004, 0.0006, 0.0008, 0.0010, 0.0013, 0.0014, 0.0015, 0.0016, 0.0018, 0.0020, 0.0021, 0.0022, 0.0024, 0.0026, 0.0028, 0.0030, 0.0032, 0.0035, 0.0037, 0.0040, or 0.0042 g CO/100 g aqueous solution.
- Preferred ranges include, e.g., about 0.0010 to about 0.0030 g CO/100 g liquid, about 0.0015 to about 0.0026 g CO/100 g liquid, or about 0.0018 to about 0.0024 g CO/100 g liquid.
- the saturation point is about 0.0044 g CO/100 g medium.
- Any suitable liquid can be saturated to a set concentration of carbon monoxide via gas diffusers.
- pre-made solutions that have been quality controlled to contain set levels of carbon monoxide can be used. Accurate control of dose can be achieved via measurements with a gas permeable, liquid impermeable membrane connected to a carbon monoxide analyzer. Solutions can be saturated to desired effective concentrations and maintained at these levels. In both liquid and gaseous compositions, the inclusion of the inert gas helium can improve carbon monoxide delivery to the tissues of an organ.
- the present invention contemplates the use of carbon monoxide compositions to treat donors, recipients, organs, tissues, masses of cells, and/or individual cells at any step of the harvesting, storage and transplant process.
- An organ, a tissue, a mass of cells, or individual cells may be harvested from a donor, treated with a carbon monoxide composition ex vivo in accordance with the present invention, and transplanted into a recipient.
- the organ, tissue, mass of cells, or individual cells can be treated in situ, while still in the donor.
- a carbon monoxide composition can be administered to the recipient prior to, during, and/or after the surgery: e.g., after an organ is reperfused with the recipient's blood.
- the carbon monoxide composition may also be administered to the donor prior to or during the process of harvesting the organ, tissue, mass of cells, or individual cells.
- Organs, tissues, masses of cells, and/or isolated cells can be harvested from a donor and transplanted by any methods known to those of skill in the art (see, for example, Oxford Textbook of Surgery , Morris and Malt, Eds., Oxford University Press (1994)). The skilled practitioner will recognize that methods for harvesting and transplantation may vary depending upon many circumstances, such as the type of organ, tissue or cells and the type of donor.
- the methods described herein can be used with organs, tissue, masses of cells or isolated cells ex vivo, e.g., bioartificial organs, such as a bioartificial liver, kidney or pancreas (see, e.g., Sambanis et al., Cytotechnology 15:351–363, 1994).
- the organs, tissues, or cells can be treated with carbon monoxide either prior to putting them in the device, or while they are utilized in the device, or both.
- the donor animal can be administered carbon monoxide prior to removal of the organ, tissue, mass of cells, or individual cells for use in the device.
- a cell can be cultured as described below and transplanted into a recipient.
- a patient can be treated with a carbon monoxide composition by any method known in the art of administering gases and/or liquids to patients.
- the present invention contemplates the systemic administration of liquid or gaseous carbon monoxide compositions to patients (e.g., by inhalation and/or ingestion), and the topical administration of the compositions to the patient's organs or tissues in situ (e.g., by ingestion, insufflation, and/or introduction into the abdominal cavity).
- the present invention also contemplates the use of carbon monoxide compositions to treat patients to inhibit endothelial cell apoptosis, e.g., as it occurs during hyperoxia, endotoxic shock, arteriosclerosis, ischemia reperfusion injury, and acute or chronic graft rejection.
- Gaseous carbon monoxide compositions can be delivered systemically to a patient, e.g., a patient undergoing or in need of a transplant. Gaseous carbon monoxide compositions are typically administered by inhalation through the mouth or nasal passages to the lungs, where the carbon monoxide is readily absorbed into the patient's bloodstream.
- concentration of active compound (CO) utilized in the therapeutic gaseous composition will depend on absorption, distribution, inactivation, and excretion (generally, through respiration) rates of the carbon monoxide as well as other factors known to those of skill in the art.
- Carbon monoxide (concentrations can vary) can be purchased mixed with air or another oxygen-containing gas in a standard tank of compressed gas (e.g., 21% O 2 , 79% N 2 ). It is non-reactive, and the concentrations that are required for the methods of the present invention are well below the combustible range (10% in air).
- the gas presumably will be delivered to the bedside where it will be mixed with oxygen or house air in a blender to a desired concentration.
- the patient will inhale the gas mixture through a ventilator, which will be set to a flow rate based on patient comfort and needs. This is determined by pulmonary graphics (i.e., respiratory rate, tidal volumes, etc.).
- Fail-safe mechanism(s) to prevent the patient from unnecessarily receiving greater than desired amounts of carbon monoxide can be designed into the delivery system.
- the patient's carbon monoxide level can be monitored by studying (1) carboxyhemoglobin (COHb), which can be measured in venous blood, and (2) exhaled carbon monoxide collected from a side port of the ventilator.
- COHb carboxyhemoglobin
- Carbon monoxide exposure can be adjusted based upon the patient's health status and on the basis of the markers. If necessary, carbon monoxide can be washed out of the patient by switching to 100% O 2 inhalation. Carbon monoxide is not metabolized; thus, whatever is inhaled will ultimately be exhaled except for a very small percentage that is converted to CO 2 .
- Carbon monoxide can also be mixed with any level of O 2 to provide therapeutic delivery of carbon monoxide without consequential hypoxic conditions.
- a carbon monoxide-containing gas mixture is prepared as above to allow inhalation by the patient using a facemask or tent.
- the concentration inhaled can be changed and can be washed out by simply switching over to 100% O 2 .
- Monitoring of carbon monoxide levels would occur at or near the mask or tent with a fail-safe mechanism that would prevent too high of a concentration of carbon monoxide from being inhaled.
- Compressed carbon monoxide can be packaged into a portable inhaler device and inhaled in a metered dose, for example, to permit intermittent treatment of a recipient who is not in a hospital setting.
- Different concentrations of carbon monoxide could be packaged in the containers.
- the device could be as simple as a small tank (e.g., under 5 kg) of appropriately diluted CO with an on-off valve and a tube from which the patient takes a whiff of CO according to a standard regimen or as needed.
- An artificial lung designed for O 2 delivery and CO 2 removal can be used for carbon monoxide delivery.
- the catheter when implanted, resides in one of the large veins and would be able to deliver carbon monoxide at given concentrations either for systemic delivery or at a local site.
- the delivery can be a local delivery of a high concentration of carbon monoxide for a short period of time at a specific site (this high concentration would rapidly be diluted out in the bloodstream), or a relatively longer systemic exposure to a lower concentration of carbon monoxide (see, e.g., Hattler et al., Artif. Organs 18(11):806–812, 1994; and Golob et al., ASAIO J. 47(5):432–437, 2001).
- the patient would be inside an airtight chamber that would be flooded with carbon monoxide (at a level that does not endanger the patient, or at a level that poses an acceptable risk without the risk of bystanders being exposed).
- the chamber could be flushed with air (e.g., 21% O 2 , 79% N 2 ), and samples could be analyzed by carbon monoxide analyzers to ensure no carbon monoxide remains before allowing the patient to exit the exposure system.
- aqueous solutions comprising carbon monoxide can be created for systemic delivery to a patient, e.g., for oral delivery and/or by injection into the body, e.g., intravenously, intra-arterially, intraperitoneally and/or subcutaneously.
- Preservation buffers and culture media can be saturated to a set concentration of carbon monoxide via gas diffusers or pre-made stock solutions that have been quality controlled to contain set levels of carbon monoxide. Accurate control of dose can be achieved via measurements with a gas permeable, liquid impermeable membrane connected to a carbon monoxide analyzer.
- the buffers and solutions can be saturated to desired effective concentrations and maintained at these levels.
- pre-made saturated solutions can be on hand to maintain the levels of carbon monoxide. If carbon monoxide levels drop, fresh solutions can be added to replace those where carbon monoxide concentrations have dropped.
- the present invention features methods of transplanting an organ(s), tissues, masses of cells and/or isolated cells.
- the methods can include a step of exposing the organ(s), tissues, mass of cells and/or isolated cells to a carbon monoxide composition prior to transplantation. Such exposures can occur in situ and/or ex vivo.
- the organ(s), tissues and/or isolated cells may be exposed to an atmosphere comprising carbon monoxide gas, to a liquid carbon monoxide composition, e.g., a liquid perfusate, storage solution, or wash solution having carbon monoxide dissolved therein, or both.
- Exposure of an organ or tissue to liquid carbon monoxide compositions can be performed ex vivo and/or in situ by any method known in the art.
- the exposure may be performed ex vivo in any chamber or space having sufficient volume for submerging the organ or tissue, completely or partially, in the carbon monoxide composition.
- the organ may be exposed to a carbon monoxide composition by placing the organ in any suitable container, and causing the carbon monoxide composition to “wash over” the organ, such that the organ is exposed to a continuous flow of the carbon monoxide composition.
- the organ may be perfused with a carbon monoxide composition.
- perfusion is an art recognized term, and relates to the passage of a liquid, e.g., a carbon monoxide composition, through the blood vessels of an organ or tissue. Methods for perfusing organs ex vivo and in situ are well known in the art.
- An organ can be perfused with a carbon monoxide composition ex vivo, for example, by continuous hypothermic machine perfusion (see Oxford Textbook of Surgery , Morris and Malt, Eds., Oxford University Press, 1994).
- the organ in in situ or ex vivo perfusions, can be perfused with a wash solution, e.g., UW solution without carbon monoxide, prior to perfusion with the carbon monoxide composition, to remove the donor's blood from the organ.
- a wash solution e.g., UW solution without carbon monoxide
- the wash solution can be a carbon monoxide composition.
- An appropriate liquid may be passed through tubing that allows gas diffusion; this tubing runs through an atmosphere comprising carbon monoxide (e.g., through a chamber, such as with extracorporeal membrane oxygenation), to create a liquid carbon monoxide composition, which may then be passed into an organ (e.g., perfused into the organ by connecting the tubing to the organ).
- an atmosphere comprising carbon monoxide (e.g., through a chamber, such as with extracorporeal membrane oxygenation)
- an organ e.g., perfused into the organ by connecting the tubing to the organ).
- the organ or tissue may be placed, e.g., submerged, in a medium or solution that does not include carbon monoxide, and placed in a chamber that exposes thee medium or solution to a carbon monoxide-containing atmosphere.
- carbon monoxide can be “bubbled” into the medium or solution.
- In situ exposures can be performed by any method known in the art, e.g., by in situ flushing or perfusion of the organ with a liquid carbon monoxide composition (see Oxford Textbook of Surgery , Morris and Malt, Eds., Oxford University Press, 1994).
- the present invention contemplates that any or all of the above methods for exposing an organ or tissue to a liquid carbon monoxide composition, e.g., washing, submerging, or perfusing, can be used in a given transplantation procedure.
- a solid or semi-solid carbon monoxide composition can be created.
- a liquid that is a carbon monoxide composition, as described above can be made into a solid or semi-solid composition, in which an organ or tissue may be overlaid or embedded.
- a semi-solid carbon monoxide composition can be infused into the organ.
- Solid or semi-solid compositions can be made, for example, by adding a solidifying agent such as a gelling agent (e.g., collagen or alginate) to the liquid.
- the present invention features a method of maintaining or culturing an animal cell in vitro.
- the method can include the steps of providing a vessel containing a pressurized gas comprising carbon monoxide gas, providing an animal cell in vitro and releasing the pressurized gas from the vessel to form an atmosphere that includes the carbon monoxide gas.
- the animal cell is then cultured or simply maintained in the presence of the atmosphere comprising carbon monoxide gas.
- the method can be performed in any chamber or space suitable for creating an atmosphere that includes appropriate levels of carbon monoxide gas.
- chambers or spaces include, e.g., incubators, mixing cylinders, and any vessel suitable for culturing or holding cells, such as roller bottles, cell culture flasks, petri dishes, and test tubes.
- a CO 2 incubator may be used, wherein carbon monoxide gas is supplied in a continuous flow from a vessel that contains the gas.
- a roller bottle may be used, wherein carbon monoxide is included to create an appropriate atmosphere inside the roller bottle.
- culture conditions e.g., temperature
- culture conditions can be selected and/or varied depending upon the type of cell to be cultured (see, for example, Cells: A Laboratory Manual , Spector and Leinwand, Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1997).
- the murine insulinoma cell line ⁇ TC3 (DSMZ, Braunschweig, Germany) can be incubated in humidified 5% CO 2 /95% air at 37° C.
- the animal cell may be disposed, e.g., suspended or bathed in, a liquid medium.
- the medium can be any medium known to those of skill in the art to be suitable for culturing, preserving, or washing the cells of interest (see, for example, Cells: A Laboratory Manual , Spector and Leinwand, Eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1997).
- types of media include, but are not limited to, various buffers, Eagle's minimal essential medium (MEM), Dulbecco/Vogt modified Eagle's minimal essential medium (DMEM), or Roswell Park Memorial Institute (RPMI) Medium.
- Such media may also comprise appropriate supplements, e.g., fetal bovine serum (FBS), individual amino acids, antibiotics, and/or vitamins.
- FBS fetal bovine serum
- the medium can be RPMI medium 1640 (Life Technologies, Grand Island, N.Y.) supplemented with 2 mM L-glutamine, 100 U/ml penicillin G, 100 U/ml streptomycin and 10% Fetal Calf Serum (FCS) (Life Technologies).
- FBS fetal bovine serum
- the medium can be RPMI medium 1640 (Life Technologies, Grand Island, N.Y.) supplemented with 2 mM L-glutamine, 100 U/ml penicillin G, 100 U/ml streptomycin and 10% Fetal Calf Serum (FCS) (Life Technologies).
- FCS Fetal Calf Serum
- the liquid medium itself is a carbon monoxide composition, created as described above.
- the medium can be infused with carbon monoxide before or following addition of the cells to the medium.
- a solid or semi-solid medium can be created wherein the solid or semi-solid medium is a carbon monoxide composition.
- a liquid medium that is a carbon monoxide composition, as described above can be made into a solid or semi-solid medium, in which cells may be overlaid or embedded.
- Such a process can be carried out, for example, by adding a gelling agent such as collagen, alginate or agar to a medium.
- HO-1 hemeoxygenase-1
- induction or expression of hemeoxygenase-1 (HO-1) in conjunction with administration of carbon monoxide.
- HO-1 can be provided to a patient by inducing or expressing HO-1 in the patient, or by administering exogenous HO-1 directly to the patient.
- induce(d) means to cause increased production of a protein, e.g., HO-1, in isolated cells or the cells of a tissue, organ or animal using the cells' own endogenous (e.g., non-recombinant) gene that encodes the protein.
- HO-1 can be induced in a patient, e.g., a donor and/or recipient, by any method known in the art.
- production of HO-1 can be induced by hemin, by iron protoporphyrin, or by cobalt protoporphyrin.
- non-heme agents including heavy metals, cytokines, hormones, nitric oxide, COCl 2 , endotoxin and heat shock are also strong inducers of HO-1 expression (Otterbein et al., Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1029–L1037, 2000; Choi et al., Am. J. Respir. Cell Mol. Biol.
- HO-1 is also highly induced by a variety of agents and conditions that create oxidative stress, including hydrogen peroxide, glutathione depletors, UV irradiation and hyperoxia (Choi et al., Am. J. Respir. Cell Mol. Biol. 15: 9–19, 1996; Maines, Annu. Rev. Pharmacol. Toxicol. 37:517–554, 1997; and Keyse et al., Proc. Natl. Acad. Sci.
- a “pharmaceutical composition comprising an inducer of HO-1” means a pharmaceutical composition containing any agent capable of inducing HO-1 in a patient, e.g., any of the agents described above, e.g., hemin, iron protoporphyrin, and/or cobalt protoporphyrin.
- HO-1 expression in a cell can be increased via gene transfer.
- the term “express(ed)” means to cause increased production of a protein, e.g., HO-1 or ferritin, in isolated cells or the cells of a tissue, organ or animal using an exogenously administered gene (e.g., a recombinant gene).
- the HO-1 or ferritin is preferably of the same species (e.g., human, mouse, rat, etc.) as the transplant recipient, in order to minimize any immune reaction.
- Expression could be driven by a constitutive promoter (e.g., cytomegalovirus promoters) or a tissue-specific promoter (e.g., milk whey promoter for mammary cells or albumin promoter for liver cells).
- a constitutive promoter e.g., cytomegalovirus promoters
- tissue-specific promoter e.g., milk whey promoter for mammary cells or albumin promoter for liver cells.
- An appropriate gene therapy vector e.g., retrovirus, adenovirus, adeno associated virus (AAV), pox (e.g., vaccinia) virus, human immunodeficiency virus (HIV), the minute virus of mice, hepatitis B virus, influenza virus, Herpes Simplex Virus-1, and lentivirus
- encoding HO-1 or ferritin would be administered to the patient orally, by inhalation, or by injection at a location appropriate for treatment of transplant rejection.
- plasmid vectors encoding HO-1 or apo-ferritin can be administered, e.g., as naked DNA, in liposomes, or in microparticles.
- exogenous HO-1 protein can be directly administered to a patient by any method known in the art.
- Exogenous HO-1 can be directly administered in addition to, or as an alternative, to the induction or expression of HO-1 in the patient as described above.
- the HO-1 protein can be delivered to a patient, for example, in liposomes, and/or as a fusion protein, e.g., as a TAT-fusion protein (see, e.g., Becker-Hapak et al., Methods 24:247–256, 2001).
- any of the products of metabolism by HO-1 e.g., bilirubin, biliverdin, iron, and/or ferritin
- bilirubin e.g., bilirubin, biliverdin, iron, and/or ferritin
- iron-binding molecules other than ferritin e.g., desferoxamine (DFO), iron dextran, and/or apoferritin
- DFO desferoxamine
- Any of the above compounds can be administered to the patient topically and/or systemically.
- nitric oxide NO
- This technique includes providing NO to the donor, the recipient, or the gorgan, tissue or cell ex vivo, in conjunction with the administration of HO-1 and/or any or all of the products of heme degradation, e.g., CO, biliverdin, bilirubin, iron, and ferritin.
- nitric oxide (or “NO”) as used herein describes molecular nitric oxide in its gaseous state or dissolved in aqueous solution.
- Gaseous compositions comprising NO are typically administered by inhalation through the mouth or nasal passages to the lungs, where the NO may exert its effect directly or be readily absorbed into the patient's bloodstream.
- Compressed or pressurized gas e.g., NO (and/or CO, as described in further detail above
- useful in the methods of the invention can be obtained from any commercial source, and in any type of vessel appropriate for storing compressed gas. If desired, the methods of the present invention can be performed using multiple vessels containing individual gases. Alternatively, CO and NO can be combined in a single vessel, diluted if desired in an inert gas.
- NO for inhalation is available commercially (e.g., INOmaxTM, INO Therapeutics, Inc., Clinton, N.J.).
- the gas may be obtained from commercial supplier typically as a mixture of 200–800 ppm NO in pure N 2 gas.
- the source of NO can be essentially 100% NO, or diluted with N 2 or any other inert gas (e.g., helium) to any desired concentration. It is vital that the NO be obtained and stored as a mixture free of any contaminating O 2 or higher oxides of nitrogen, because such higher oxides of nitrogen (which can form by reaction of O 2 with NO) are potentially harmful to lung tissues. If desired, purity of the NO may be demonstrated with chemiluminescence analysis, using known methods, prior to administration to the patient.
- Chemiluminescence NO—NO x analyzers are commercially available (e.g., Model 14A, Thermo Environmental Instruments, Franklin, Mass.).
- the NO—N 2 mixture may be blended with an O 2 -containing gas (e.g., 100% O 2 or air) just prior to inhalation by the patient, using, for example, a calibrated rotameter that has been validated previously with a spirometer.
- the final concentration of NO in the breathing mixture may be verified with a chemical or chemiluminescence technique well known to those in the field (e.g., Fontijin et al., Anal Chem 42:575, 1970).
- NO and NO 2 concentrations may be monitored by means of an electrochemical analyzer. Any impurities such as NO 2 can be scrubbed by exposure to NaOH solutions, baralyme, or sodalime.
- the FiO 2 of the final gas mixture may also be assessed.
- compositions comprising NO can be administered using any method in the art for administering gases to patients. Safe and effective methods for administration of NO by inhalation are described in, e.g., U.S. Pat. Nos. 5,570,683; 5,904,938; and Frostell et al., Circulation 83:2038–2047, 1991. Some exemplary methods for administering gases (such as CO) to patients are described in detail above, and can be used to administer NO. Examples of methods and devices that can be utilized to administer gaseous pharmaceutical compositions comprising NO to patients include ventilators, face masks and tents, portable inhalers, intravenous artificial lungs (see, e.g., Hattler et al., Artif.
- NO can also be mixed with room air, using a standard low-flow blender (e.g., Bird Blender, Palm Springs, Calif.). NO can be generated from N 2 and O 2 (i.e., air) by using an electric NO generator. A suitable NO generator is described in U.S. Pat. No. 5,396,882.
- NO can be provided intermittently from an inhaler equipped with a source of NO such as compressed NO or an electric NO generator. The use of an inhaler may be particularly advantageous if a second compound (e.g., a phosphodiesterase inhibitor as described in further detail below) is administered, orally or by inhalation, in conjunction with the NO.
- a second compound e.g., a phosphodiesterase inhibitor as described in further detail below
- the NO concentration at the time of inhalation is about 0.1 ppm to about 300 ppm, e.g., 0.5 ppm to 290 ppm, 1.0 ppm to 280 ppm, 5 ppm to 250 ppm, 10 ppm to 200 ppm, or 10 ppm to 100 ppm, in air, pure oxygen, or another suitable gas or gas mixture.
- a suitable starting dosage for NO administered by inhalation can be 20 ppm (see, e.g., INOmaxTM package insert), and the dosage can vary, e.g., from 0.1 ppm to 100 ppm, depending on the age and condition of the patient, the disease or disorder being treated, and other factors that the treating physician may deem relevant.
- Acute, sub-acute and chronic administration of NO are contemplated by the present invention.
- NO can be delivered to the patient for a time (including indefinitely) sufficient to treat the condition and exert the intended pharmacological or biological effect.
- the concentration can be temporarily increased for short periods of time, e.g., 5 min at 200 ppm NO. This can be done when an immediate effect is desired.
- Preferred periods of time for exposure of a patient to NO include at least one hour, e.g., at least six hours; at least one day; at least one week, two weeks, four weeks, six weeks, eight weeks, ten weeks or twelve weeks; at least one year; at least two years; and at least five years.
- the patient can be exposed to the atmosphere continuously or intermittently during such periods.
- the administration of pharmaceutical compositions comprising NO (and/or CO) can be via spontaneous or mechanical ventilation.
- inhaled NO When inhaled NO is administered, it is desirable to monitor the effects of the NO inhalation. Such monitoring can be used, in a particular individual, to verify desirable effects and to identify undesirable side effects that might occur. Such monitoring is also useful in adjusting dose level, duration and frequency of administration of inhaled NO in a given individual.
- Gaseous NO can be dissolved in aqueous solution, and utilized in that form.
- aqueous solution could be used to bathe an organ, tissue or cells ex vivo, or used to perfuse an organ or tissue in situ.
- the solution can contain other active agents such as CO, HO-1, heme, biliverdin, and/or bilirubin.
- a phosphodiesterase inhibitor can be administered in conjunction with NO inhalation to inhibit the breakdown of cGMP by endogenous phosphodiesterases.
- the phosphodiesterase inhibitor can be introduced into a patient by any suitable method, including via an oral, transmucosal, intravenous, intramuscular, subcutaneous or intraperitoneal route. Alternatively, the inhibitor can be inhaled by the patient.
- the phosphodiesterase inhibitor is advantageously formulated as a dry powder or an aerosolized or nebulized solution having a particle or droplet size of less than 10 ⁇ m for optimal deposition in the alveoli, and may optionally be inhaled in a gas containing NO.
- a phosphodiesterase inhibitor can be administered in conjunction with NO inhalation to inhibit the breakdown of cGMP by endogenous phosphodiesterases.
- the phosphodiesterase inhibitor can be introduced into a patient by any suitable method, including via an oral, transmucosal, intravenous, intramuscular, subcutaneous or intraperitoneal route. Alternatively, the inhibitor can be inhaled by the patient.
- the phosphodiesterase inhibitor is advantageously formulated as a dry powder or an aerosolized or nebulized solution having a particle or droplet size of less than 10 ⁇ m for optimal deposition in the alveoli, and may optionally be inhaled in a gas containing NO.
- a suitable phosphodiesterase inhibitor is Zaprinast ⁇ hacek over (O) ⁇ (M&B 22948; 2-o-propoxyphenyl-8-azapurine-6-one; Rhone-Poulenc Rorer, Dagenham Essex, UK).
- Zaprinast ⁇ hacek over (O) ⁇ selectively inhibits the hydrolysis of cGMP with minimal effects on the breakdown of adenosine cyclic-monophosphate in vascular smooth muscle cells (Trapani et al., J Pharmacol Exp Ther 258:269, 1991; Harris et al., J Pharmacol Exp Ther 249:394, 1989; Lugnier et al., Biochem Pharmacol 35:1743, 1986; Souness et al., Br J Pharmacol 98:725, 1989).
- the preferred routes of administration are intravenous or oral.
- the suitable dose range may be determined by one of ordinary skill in the art.
- a stock solution of Zaprinast ⁇ hacek over (O) ⁇ may be prepared in 0.05 N NaOH. The stock can then be diluted with Ringer's lactate solution to the desired final Zaprinast concentration, immediately before use.
- This invention can be practiced with other phosphodiesterase inhibitors.
- Various phosphodiesterase inhibitors are known in the art, including Viagra® (sildenafil citrate) dipyridamole and theophylline.
- Viagra® sidenafil citrate
- dipyridamole dipyridamole
- theophylline a suitable route of administration and suitable dose range can be determined by one of ordinary skill in the art.
- Administration of NO with phosphodiesterase inhibitors can be performed as follows.
- the NO is administered at 20 ppm in air for 45 min.
- 1.0 mg of Zaprinast ⁇ hacek over (O) ⁇ per kg body weight is administered by intravenous infusion over 4 min, followed by a continuous infusion of 0.004 mg/kg/min for the rest of the 45 min period.
- 0.15 mg dipyridamole per kg body weight is administered over 4 min, followed by a continuous infusion of 0.004 mg/kg/min for the rest of the 45 min period.
- the Zaprinast ⁇ hacek over (O) ⁇ or dipyridamole is administered in a saline solution.
- a DST can be administered to a recipient prior to, during and/or after the administration of CO, HO-1, other heme-associated products, and/or NO to a recipient.
- administration e.g., administration of DST(s) along with a treatment described herein, can be carried out prior to, during, and/or after transplantation.
- the murine insulinoma cell line ⁇ TC3 (DSMZ, Braunschweig, Germany) was cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Life Technologies, Grand Island, N.Y., USA) supplemented with 2 mM L-glutamine, 100 U/ml penicillin G, 100 U/ml streptomycin and 10% Fetal Calf Serum (FCS) (Life Technologies) and incubated in humidified 5% CO 2 /95% air at 37° C.
- DMEM Dulbecco's Modified Eagle's Medium
- FCS Fetal Calf Serum
- the cells produce mature insulin from proinsulin I and II in a manner comparable to ⁇ -cells in vivo and are inducible up to 30 fold by glucose (Efrat et al., Proc. Natl. Acad. Sci. USA 85:9037–41, 1988). Compared to other frequently used transformed ⁇ -cell lines such as RIN-m5F and HIT, levels of secreted insulin are closer to normal ⁇ -cells in the ⁇ TC3 cell line. Thus, these cells are useful for studying ⁇ -cell regulation and gene expression (D'Ambra et al., Endocrinology 726:2815–22, 1990).
- Pancreatic islets of Langerhans of C57BL/6 mice were supplied by the islet isolation core facility of the Joslin Diabetes Center.
- ⁇ TC3 were seeded at 2 ⁇ 10 5 cells (Nunc, Marsh Products, Rochester, N.Y., USA). Cells were washed once with 500 ⁇ l PBS and stained with 200 ⁇ l 0.05% Crystal Violet in 20% ethanol for 10 min at RT. Crystal Violet was rinsed. To elute stain from cells, 100 ⁇ l 50% acetic acid were added to each well. 50 ⁇ l were transferred into a 96 well microtiter plate and read with a microtiter plate reader (EL 340 biokinctics reader, Bio-Tek Instruments) at an absorbance of 562 nm.
- EL 340 biokinctics reader Bio-Tek Instruments
- the ⁇ -galactosidase expression vector (Clontech Laboratories, Palo Alto, Calif.) was cloned into the pcDNA3 vector (Sato et al., J. Immunol. 166:4185–4194, 2001). (Invitrogen, Carlsbad, Calif.). A 1.0 kbp XhoI-HindIII fragment encoding the full length rat HO-1 cDNA was cut from the prHO-1 vector (Shibahara et al., J. Biochem. 113:214–218, 1993) and sub-cloned into the pcDNA3 vector.
- ⁇ TC3 were seeded at 3 ⁇ 10 5 cells in 16 mm wells and transfected 15 to 20 hours later using Lipofectamine plusTM reagents (Life Technologies) according to the manufacturer's instructions. Total DNA was maintained constant using empty pcDNA3 vector. The percentage of viable cells was assessed by normalizing the percentage of viable cells of each DNA preparation to the number of control-transfected cells without the apoptotic stimulus (100% viability) (Soares et al., Nature Med. 4:1073–1077, 1998; Sato et al., J. Immunol. 166:4185–4194, 2001).
- ⁇ TC3 cultures were incubated with recombinant TNF- ⁇ (500 or 1000 U/ml) (R&D Systems) for 24 hours and islet cultures were stimulated with TNF-É (5000 U/ml) (R&D Systems) and cyclohexamide (CHX) (50 ⁇ g/ml) for 48 hours.
- ⁇ TC3 or islets were harvested, dispersed, fixed in 70% ethanol, and suspended in DNA staining buffer (PBS, pH 7.4, containing 0.1% Triton X-100, 0.1 mM EDTA, 50 ⁇ g/ml propidium iodide, 50 mg/ml Rnase A).
- DNA content was analyzed on a FACScanTM analyzer equipped with Cell Quest ⁇ hacek over (O) ⁇ Software (Becton Dickinson, Palo Alto, Calif.). Cells with a normal DNA content (2N) were scored as viable, whereas cells with a hypoploid DNA content ( ⁇ 2N, termed A 0 ) were scored as apoptotic. To exclude debris and apoptotic cell-free fragments, all events with an FL-2 area profile below that of chicken erythrocyte nuclei were excluded from analysis.
- the caspase-3 inhibitor Z-DEVD-FMK and the caspase-8 inhibitor IETD-CHO (Calbiochem, San Diego, Calif.) were dissolved in dimethyl sulphoxide (DMSO, Sigma) and added to the culture medium (10 ⁇ M and 1 ⁇ M respectively) two hours before treatment with TNF- ⁇ .
- Tin protoporphyrin (SnPPIX) (Porphyrin Products, Logan, Utah) was dissolved (10 mM) in 100 mM NaOH and added 6 hours after transfection to the culture medium (50 ⁇ M).
- the guanylyl cyclase inhibitor 1H[1,2,4]oxadiazolo[4,3- ⁇ ]quinoxalin-1 (ODQ; Calbiochem) was dissolved in DMSO and added to the culture medium (100 ⁇ M) 6 hours after transfection.
- the cGMP analogue 8-bromoguanosine-3′-5′-cyclic-monophosphate (8-Br-cGMP) (Sigma) was dissolved in water and added to the culture medium (10 ⁇ M) 30 minutes before induction of apoptosis.
- the protein kinase G inhibitor KT5823 (Calbiochem) was dissolved in DMSO and added to the culture medium (1.6 ⁇ M) 6 hours after transfection.
- mice Male C57BL/6 were purchased from Charles River Laboratories (Wilmington, Mass.) and housed in accordance with guidelines from the NIH. The experiments were approved by the Institutional Animal Care and Use Committee (IACUC). Recipient mice (8 weeks old) were rendered diabetic by a single intraperitoneal injection (220 mg/kg) of Streptozotocin ⁇ hacek over (O) ⁇ (Sigma) dissolved in citrate buffer. Mice received transplants if 2 consecutive non-fasting blood glucose levels of greater than 350 mg/dl were obtained from a whole blood sample.
- IACUC Institutional Animal Care and Use Committee
- Pancreatic islets of Langerhans were provided by the Islet Core Laboratory of the JDRF Center for Islet Transplantation at Harvard Medical School and isolated as described previously (Gotoh et al., Transplantation 40:437–438, 1985).
- islets 150–250me in diameter were hand-picked using a dissecting microscope. Islets were transplanted under the kidney capsule as described previously (Kaufman et al., J. Exp. Med. 172:291–302, 1990). From each islet preparation the same numbers of control and treatment animals were transplanted.
- Graft function was defined as the point when the first of three consecutive days of non-fasting blood glucose levels ⁇ 200 mg/dl was reached.
- the primary endpoint of the experiment was defined as time to normoglycemia.
- Blood glucose data were summarized as mean ⁇ standard deviation of mice receiving untreated or treated islets.
- Time to recovery of islet function was calculated using Kaplan-Meier life tables and differences between groups tested using a log-rank test, with the three islet preparations treated as separate strata in the analysis, and the median time to recovery, with 95% confidence interval, reported.
- FIGS. 1A–C The effect of TNF- ⁇ on ⁇ TC3 cells was investigated. The following procedures were utilized to generate the data illustrated in FIGS. 1A–C .
- FIG. 1A ⁇ TC3 were treated with increasing concentrations of TNF- ⁇ . Viable cells were stained 24 hours after activation by crystal violet. The extinction was measured at 562 nm and normalized to untreated cells.
- FIG. 1B ⁇ TC3 were treated with TNF- ⁇ , stained by propidium iodide 24 hours later and analyzed for DNA fragmentation (FACScanTM).
- FIG. 1C ⁇ TC3 were co-transfected with a ⁇ -gal expressing vector (pcDNA3/ ⁇ -gal) plus control (pcDNA3).
- TNF- ⁇ induced high levels of cell death in the insulinoma cell line ⁇ TC3, in a dose-dependent manner (Stephens et al., Endocrinology 140:3219–3227, 1999) ( FIG. 1A ). DNA fragmentation was demonstrated by propidium iodide (PI) staining ( FIG. 1B ), suggesting that TNF- ⁇ induces ⁇ -cell death through apoptosis.
- PI propidium iodide
- TNF- ⁇ mediated apoptosis was strictly dependent on the activation of caspase-8 and partially dependent on that of caspase-3, as illustrated by the finding that blocking caspase-8 with a specific caspase-8 inhibitor (IETD-CHO) prevented apoptosis (96% inhibition) while blocking caspase-3 by a specific caspase-3 inhibitor (Z-DEVD-FMK) prevented apoptosis only partially (53% inhibition) ( FIG. 1C ).
- IETD-CHO specific caspase-8 inhibitor
- Z-DEVD-FMK Z-DEVD-FMK
- FIGS. 2A–C Whether exogenous carbon monoxide could protect ⁇ -cells from apoptosis was investigated. The following procedures were utilized to generate the data illustrated in FIGS. 2A–C .
- FIG. 2A Exogenous CO can substitute for HO-1 when HO-1 activity is blocked.
- ⁇ TC3 were co-transfected with a ⁇ -gal expressing vector plus control or HO-1-expressing rector (Brouard et al., J. Exp. Med. 192:1015–1026, 2000). When indicated, HO-1 enzymatic activity was inhibited by tin protoporphyrin (SnPP).
- SnPP tin protoporphyrin
- FIG. 2B Exogenous carbon monoxide protects ⁇ -cells from apoptosis in the DNA fragmentation analysis.
- ⁇ TC3 were treated with TNF- ⁇ . Directly after stimulation, ⁇ TC3 were exposed to exogenous carbon monoxide for 24 hours. Control ⁇ TC3 were treated in the same manner but not exposed to carbon monoxide.
- FIG. 2C Exogenous carbon monoxide protects ⁇ -cells from apoptosis in absence of HO-1.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors and were exposed to exogenous carbon monoxide (Stephens et al., Endocrinology 740:3219–27, 1999). Gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ or etoposide or subjected to serum deprivation as indicated. Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- ⁇ TC3 cells were transiently transfected with a HO-1 expression vector and tested for their ability to survive when exposed to TNF- ⁇ .
- Over-expression of HO-1 protected ⁇ TC3 from TNF- ⁇ mediated apoptosis (Pileggi et al., Diabetes 50:1983–1991, 2001) (87% survival versus 33% in control) ( FIG. 2A ).
- SnPPIX tin protoporphyrin IX
- FIG. 2A the anti-apoptotic effect was suppressed ( FIG. 2A ), suggesting that the generation of at least one of the end products of heme catabolism by HO-1, i.e. iron, bilirubin and/or CO, is required for its anti-apoptotic function.
- FIG. 3 Whether exogenous carbon monoxide protects murine islet cells from apoptosis was also investigated ( FIG. 3 ). The following procedures were utilized to generate the data illustrated in FIG. 3 . Apoptosis was induced in freshly isolated murine islets (C57BL/6) by stimulation with TNF- ⁇ and cycloheximide (CHX). Directly after stimulation, islets were exposed to exogenous carbon monoxide for 24 hours. Control islets were treated in the same manner but not exposed to carbon monoxide. After 48 hours cells were analyzed on a FACScanTM for DNA fragmentation. This experiment was done twice with indistinguishable results.
- CHX cycloheximide
- FIGS. 4A–C Whether the anti-apoptotic effect of carbon monoxide acted via activation of soluble guanylate cyclase (sGC) and generation of cGMP was investigated ( FIGS. 4A–C ). The following procedures were utilized to generate the data illustrated in FIGS. 4A–C .
- FIG. 4A The anti-apoptotic effect of exogenous carbon monoxide is mediated by guanylate cyclase activation.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors and exposed to exogenous carbon monoxide (1%). Where indicated, ⁇ TC3 were treated with the guanylyl cyclase inhibitor ODQ.
- FIG. 4A The anti-apoptotic effect of exogenous carbon monoxide is mediated by guanylate cyclase activation.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors and exposed to exogenous carbon monoxide (1%). Where indicated, ⁇ TC
- FIG. 4B A cGMP analogue can substitute for carbon monoxide in protecting from apoptosis.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors. Where indicated, ⁇ TC3 were exposed to exogenous carbon monoxide. Where indicated, ⁇ TC3 were treated with the cGMP analogue 8-Br-cGMP but not exposed to carbon monoxide.
- FIG. 4C cGMP-dependent protein kinases (cGK) mediate the anti-apoptotic effect of carbon monoxide.
- ⁇ TC3 were co-transfected with ⁇ -gal expressing vector. When indicated, ⁇ TC3 were exposed to exogenous carbon monoxide.
- FIGS. 5A–C The ability of carbon monoxide to protect ⁇ -cells after induction of apoptosis was investigated ( FIGS. 5A–C ). The following procedures were utilized to generate the data illustrated in FIGS. 5A–C .
- FIG. 5A one hour of carbon monoxide exposure is sufficient to prevent apoptosis.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors. Apoptosis of ⁇ -cells was induced by TNF- ⁇ . Immediately after TNF- ⁇ activation, cells were exposed to 1% carbon monoxide for varying periods (0–24 hours). Control ⁇ TC3 were treated in the same manner but were not exposed to carbon monoxide. Cell survival was determined 24 hours after application of TNF- ⁇ .
- FIG. 5A one hour of carbon monoxide exposure is sufficient to prevent apoptosis.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors. Apoptosis of ⁇ -cells was induced by TNF
- FIG. 5B carbon monoxide protects ⁇ -cells after induction of apoptosis.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors. Apoptosis was induced by TNF- ⁇ . After varying periods (0.5–12 hours, as indicated), ⁇ TC3 were exposed to 1% carbon monoxide (Otterbein et al., Nat. Med, 6:422–428, 2000). Control ⁇ TC3 were treated in the same manner but were not exposed to carbon monoxide. Cell survival was determined 24 hours after application of TNF- ⁇ .
- FIG. 5C Preincubation with carbon monoxide prevents ⁇ -cell apoptosis.
- ⁇ TC3 were transfected with ⁇ -gal expressing vectors and apoptosis was induced by TNF- ⁇ .
- ⁇ TC3 were pre-exposed to 1% carbon monoxide for one hour.
- Control ⁇ TC3 were treated in the same manner but were not exposed to carbon monoxide. 1–6 hours after termination of the pre-exposure, apoptosis was induced by TNF- ⁇ .
- Gray histograms represent untreated ⁇ -cells and black histograms represent ⁇ -cells treated with TNF- ⁇ . Results shown are mean ⁇ standard deviation from duplicate wells taken from one representative experiment out of three.
- ⁇ TC3 were exposed to carbon monoxide for different time periods (1–24 hours) immediately after the addition of TNF- ⁇ and tested for apoptosis 24 hours later. One hour of carbon monoxide exposure was sufficient to prevent ⁇ -cell apoptosis ( FIG. 5A ).
- ⁇ TC3 were exposed to carbon monoxide for 0.5 to 3 hours before apoptosis induction.
- One hour pre-incubation in the presence of carbon monoxide was sufficient to prevent ⁇ -cell apoptosis (data not shown).
- ⁇ -cells were preexposed for one hour to CO, one to six hours before induction of apoptosis with TNF- ⁇ ( FIG. 5C ).
- a marginal islet mass of 250 handpicked islets was transplanted in a syngeneic system, a model for primary non-function (Berney et al., Transplantation 71:125–32, 2001); Kaufman et al., Diabetes 43:778–83, 1994).
- Transplantation of a marginal (e.g., sub-optimal) number of islets (a “marginal mass”) into a diabetic syngeneic recipient causes a delay in the return to normoglycemia without the effects of rejection or recurrence of auto-immune disease.
- FIGS. 6A–B Whether carbon monoxide pre-incubation of islet grafts prior to transplantation results in better functional performance in vivo was investigated ( FIGS. 6A–B ). The following procedures were utilized to generate the data illustrated in FIGS. 6A–B .
- FIG. 6A Two hundred and fifty freshly isolated and hand-picked islets from C57BL/6 mice were incubated in medium pre-saturated with 1% carbon monoxide for two hours at 37° C. Control islets were treated in the same manner but were not exposed to carbon monoxide. The islets were transplanted under the kidney capsule of the diabetic syngeneic recipients as described previously. After transplantation, blood glucose levels were determined on a daily basis.
- CO 2 For cell culture experiments, 5% CO 2 is present for buffering requirements. CO at a concentration of 1% (10,000 ppm) in compressed air is mixed with compressed air with or without CO 2 in a stainless steel mixing cylinder before delivery into the exposure chamber. Flow into the 3.70-ft 2 plexiglass animal chamber is maintained at 12 L/min and into the 1.2-ft 2 cell culture chamber at a flow of 2 L/min. The cell culture chamber is humidified and maintained at 37° C. A CO analyzer (Interscan, Chatsworth, Calif.) is used to measure CO levels continuously in the chambers.
- the following example illustrates a protocol used for the isolation of islet cells from rats or mice.
- Rat Liberase ⁇ hacek over (O) ⁇ (from Boehringer Manheim/Roche cat. # 1 815 032) was dissolved in 4 ml of sterile HBSS, chilled on ice for 30 min, aliquoted into 0.5 ml aliquots, and stored at ⁇ 20° C.
- 33 ml of medium e.g., M199, HBSS or RPMI 1640 without calf serum, was added.
- Rats were overdosed with anesthesia (0.1 ml plus 0.1 ml/100 g body weight of Nembutol I.P.).
- 3 ml syringes were prepared with 2 ml of Liberase solution with a 27 g-needle bent at a 90-degree angle.
- 2 pairs of scissors were used; one large pair for the abdominal cut and one fine pair to snip the bile duct.
- Two pairs of forceps were used for excision of the pancreas.
- One hemostat was used to clamp off the bile duct.
- the abdomen was opened and the pancreas was exposed as much as possible by making a v cut from the lower abdomen.
- the pancreatic duct was clamped off (with a hemostat in rats or a small bulldog clamp in mice) at its duodenal insertion, taking care not to injure the surrounding pancreatic tissue.
- the bile duct was isolated at the proximal end. Fat was removed before inserting the cannula, making sure not to puncture the portal vein.
- the duct was cut with the fine scissors one third of the way across and the cannula was inserted in the duct.
- the cannula was held in the duct by clamping the duct lightly with forceps. Liberase ⁇ hacek over (O) ⁇ solution was injected rapidly.
- pancreas appeared to be distended and fully dilated after 6 mls of fluid injection.
- the needle was inserted into the duct as proximal to the liver as possible and Liberase ⁇ hacek over (O) ⁇ solution was injected.
- the rat or mouse was then sacrificed by cutting the diaphragm and heart or aorta.
- pancreas After Liberase ⁇ hacek over (O) ⁇ infiltration, the pancreas was removed, starting by removing from the intestines, then the stomach and then the spleen. When the pancreas was attached only by the bile duct, it was cut out of the rat. The pancreas was placed in a 50 ml conical tube, and placed in a water bath at 37° C. for 30 min.
- the tissue was resuspended in 20 ml of medium, and the suspension was filtered through a 400for diameter wire mesh (Thomas scientific mesh 35 cat. # 8321-M22) to remove the remaining undigested tissue, fat and lymph. 5–10 ml more was added to the tube to wash any remaining islets off and filter through the mesh.
- the cells were pelleted by spinning at 1200 rpm for 90 sec. The supernatant was removed, leaving as little excess medium as possible.
- the pellet was resuspended in 10–15 ml Histopaque 1077 ⁇ hacek over (O) ⁇ (Sigma cat # H 1077) and vortexed until the suspension was homogeneous (same as for washes).
- 10 ml of medium was overlaid, without NCS, being careful to maintain the sharp interface between the Histopaque ⁇ hacek over (O) ⁇ and the medium.
- the medium was added by pipetting slowly down the side of the tube.
- the gradient was centrifuged for 20 minutes at 2400 rpm (900 g) at 10° C. with very slow acceleration and no braking.
- the islet layer was collected from the interface with a disposable 10 cc serologic pipette (Falcon), and placed in 50 cc conical tubes. Islets were washed several times to remove the Histopaque ⁇ hacek over (O) ⁇ by adding 25–35 ml of the medium+NCS. The initial centifugation was performed at 1200 rpm for 2 min., but the subsequent centrifugations were performed for 90 sec. After the 3 washes, the islets were resuspended by pipetting up and down. 7–10 ml each were put on 60 mm sterile culture dishes for hand picking.
- Falcon 10 cc serologic pipette
- BALB/c mouse hearts were used as donor organs for transplantation into inbred adult male Lewis rats (Harlan Sprague-Dawley, Indianapolis, Ind.). Animals were housed in accordance with guidelines from the American Association for Laboratory Animal Care, and research protocols were approved by the Institutional Animal Care and Use Committees of the Beth Israel Deaconess Medical Center.
- Cobra venom factor (CVF; which blocks complement activation) (Quidel, San Diego, Calif.) was administered i.p. on day ⁇ 1 (60 U/kg) and on day 0 (20 U/kg) with respect to the day of transplantation (day 0).
- Cyclosporin A (CsA; Novartis, Basel, Switzerland), which blocks T cell activation, was administered i.m. (15 mg/kg) starting at day 0 and daily thereafter until the end of each experiment.
- Tin protoporphyrin SnPPIX
- CoP-PIX cobalt protoporphyrin
- FePPIX FePPIX; Porphyrin Products, Logan, Utah
- CO at a concentration of 1% (10,000 parts per million; ppm) in compressed air was mixed with balanced air (21% oxygen) in a stainless steel mixing cylinder before entering the exposure chamber.
- CO concentrations were controlled by varying the flow rates of CO in a mixing cylinder before delivery to the chamber. Because the flow rate is primarily determined by the O 2 flow, only the CO flow was changed to deliver the final concentration to the exposure chamber.
- HO enzymatic activity was measured by bilirubin generation in heart and liver microsomes. Animals were sacrificed, and the liver and hearts were flushed with ice-cold PBS and frozen at ⁇ 70° C. until used. Organs were homogenized in four volumes of sucrose (250 mM) Tris-HCl (10 mM/L) buffer (pH 7.4) on ice and centrifuged (28,000 RPM 3 ⁇ , 20 min, 4° C.).
- the supernatant was centrifuged (105,000 RPM 3 ⁇ , 60 min, 4° C.), and the microsomal pellet was resuspended in MgCl 2 (2 mM)-potassium phosphate (100 mM) buffer (pH 7.4) and sonicated on ice.
- the samples (1 mg of protein) were added to the reaction mixture (400 moto) containing rat liver cytosol (2 mg of protein), hemin (50 îM), glucose-6-phosphate (2 mM), glucose-6-phosphate dehydrogenase (0.25 U), and NADPH (0.8 mM) for 60 min at 37° C. in the dark.
- the formed bilirubin was extracted with chloroform and, OD was measured at 464–530 nm (extinction coefficient, 40 mM/cm for bilirubin). Enzyme activity is expressed as picomoles of bilirubin formed per milligram of protein per 60 min (pmol/mg/h). The protein concentration was determined by the bicinchoninic acid protein assay (Pierce, Georgetown). The background was ⁇ 5 pmol/mg/h. All reagents used in this assay were purchased from Sigma (St. Louis, Mo.), unless otherwise indicated. Carboxyhemoglobin was measured 2 days after transplantation by using a Corning 865 blood gas analyzer (Clinical Chemistry, Massachusetts General Hospital, Boston, Mass.).
- Grafts were harvested 3 days after transplantation, embedded in paraffin, fixed in formalin, and serially sectioned (506.) in toto from the apex to the base. Ten sections were placed per slide in a total of about 20–25 slides. Every fifth slide was stained with hematoxylin and eosin (H&E) for histomorphometric analysis.
- H&E hematoxylin and eosin
- Two images per slide were captured by using a Nikon Eclipse E600 ⁇ hacek over (O) ⁇ microscope (Nikon, Melville, N.Y.) connected to a Hitachi 3-CCD Color Camera (model HV-C20; Hitachi, Tokyo, Japan) and to a Power Macintosh ⁇ hacek over (O) ⁇ 7300/200 computer (Apple Computer, Cupertino, Calif.) equipped with IPLab Spectrum digital imaging software (Signal Analytics Corporation, Vienna, Va.). About 50 images were captured from each transplanted heart from two to three animals per group. Images were analyzed by manual segmentation, tracing the infarcted and noninfarcted areas from the right and left ventricles in each section.
- Rat leukocyte populations were analyzed by using anti-rat leukocyte common Ag (LCA, CD45; OX-1), Éé TCR (TCRÉé-chains; R73), B cell (CD45RB; OX-33), NK cell (NKR-P1; 3.2.3), and M ⁇ (CD68; ED-1), mAbs (Serotec, Harlan Bioproducts for Science, Indianapolis, Ind.).
- Detection of fibrin/fibrinogen was conducted by using a rabbit anti-human fibrin/fibrinogen polyclonal Ab (Dako, Carpinteria, Calif.). Intragraft complement activation was detected by using an anti-rat Clq (The Binding Site, Birmigham, U. K.), C3 (ED11; Serotec), or C5b-9 mAb (Dako). Rat IgM was detected by using the mouse anti-rat IgM mAb MARM-4 (a kind gift of Dr. H. Bazin, University of Louvain, Brussels, Belgium). Isotype-matched mAbs or purified Ig, as well as a control for residual endogenous peroxidase activity, were included in each experiment. Detection of apoptosis was carried out by using ApopTag ⁇ hacek over (O) ⁇ in situ apoptosis detection kit (Oncor, Gaithersburg, Md.) according to the manufacturer's instructions.
- Serum levels of rat anti-mouse Abs were measured by cellular-based indirect ELISA.
- the mouse 2F–2B endothelial cell line (CRL-2168; American Type Culture Collection (ATCC), Manassas, Va.) was used as an antigenic target. Briefly, 2F–2B cells were cultured in DMEM (Life Technologies, Rockville, Md.), 10% FCS, 100 U/ml penicillin, and 100 îg/ml streptomycin (Life Technologies).
- Glutaraldehyde-fixed 2F–2B cells were incubated (1 h, 37° C.) in the presence of rat serum serially diluted in PBS 0.05% Tween 20 (Sigma) and rat anti-mouse Abs were detected by using mouse anti-rat IgM (MARM-4), IgG1 (MARG1-2), IgG2a (Marg2a-1), IgG2b (MARGb-8), or IgG2c (MARG2c-5) (kind gifts from Prof. H. Bazin, University of Louvain, Brussels, Belgium).
- Binding of rat C3 to mouse endothelial cells was measured by a modified cellular ELISA with mouse 2F–2B endothelial cells as antigenic targets (Miyatake et al, J. Immunol. 160:4114, 1998). Briefly, nonfixed 2F–2B endothelial cells were incubated in the presence of rat serum serially diluted in GVB ++ buffer (1 h, 37° C.). Cells were fixed in PBS, 0.05% glutaraldehyde, and rat C3 deposition was detected by using a mouse anti-rat C3 mAb (Serotec).
- Mouse 2F–2B endothelial cells were cultured on 0.2% gelatin (Sigma) coated six-well plates in 88% DMEM (Life Technologies), 10% FCS (FCS), 100 U/ml penicillin, and 100 îg/ml streptomycin (Life Technologies). Confluent endothelial cells either were left untreated or were treated with the HO-inducing agent CoPPIX (50 îM; 18 h), the HO inhibitor SnPPIX (50 îM, 18 h), or both CoPPIX (50 îM, 15 h) and SnPPIX (50 îM, 3 h).
- Platelet-rich plasma was obtained by centrifugation (290-g, 12 min, 19° C.) of normal rat plasma in 3.8% sodium citrate. Rat platelets (3–10 8 cells ml) were resuspended in HT buffer (8.9 mM NaHCO 3 , 0.8 mM KH 2 PO, 5.6 mM dextrose, 2.8 mM KCl solution, 0.8 mM MgCl 2 , 129 mM NaCl, 10 mM HEPES). Platelets were overlaid (5 min; 37° C.) on mouse endothelial cells, and platelet aggregation assays were conducted as described before (Kaczmarek et al, J. Biol. Chem. 271:33116, 1996) by using an aggregometer (Chrono-Log, Harestown, Pa.) and ADP (0.5–4 ⁇ M) as an agonist.
- HT buffer 8.9 mM NaHCO 3 ,
- Endothelial cells were washed in PBS (pH 7.2), harvested by scraping, and lysed in Laemmli buffer. Electrophoresis was conducted under denaturing conditions with 10% polyacrylamide gels. Proteins were transferred onto a polyvinyldifluoridine membrane (immobilon P; Millipore, Bedford, Mass.) by electroblotting and detected with rabbit polyclonal Abs directed against human HO-1 or HO-2 (StressGen, Victoria, Canada) or é-tubulin (Boehringer Mannheim, Mannheim, Germany).
- Proteins were visualized by using HRP-conjugated donkey anti-rabbit IgG or goat anti-mouse IgG (Pierce) and the ECL assay (Amersham Life Science, Arlington Heights, Ill.) according to manufacturer's instructions.
- the murine 2F–2B endothelial cell line was transiently transfected as described elsewhere (Soares et al., Nature Med. 4:1073, 1998; Brouard et al, J. Exp. Med. 192:1015, 2000). All experiments were conducted 24–48 h after transfection. é-galactosidase-transfected cells were detected as described elsewhere (Soares et al., Nature Med. 4:1073, 1998; Brouard et al., J. Exp. Med. 192:1015, 2000).
- Percentage of viable cells was assessed by evaluating the number of é-galactosidase-expressing cells that retained normal morphology as described elsewhere (Soares et al., Nature Med. 4:1073, 1998; Brouard et al., J. Exp. Med. 192:1015, 2000). The number of random fields counted was determined to have a minimum of 200 viable transfected cells per control well. The percentage of viable cells was normalized for each DNA preparation to the number of transfected cells counted in the absence of the apoptosis-inducing agent (100% viability). All experiments were performed at least three times in duplicate. Actinomycin D (Act.
- Aortic transplantation was carried out as described elsewhere (Plissonnier et al., Transplantation 60:414–424, 1995). Briefly, the aorta and the inferior vena cava were cut to be bled after heparinization. After additional left thoracotomy, three or four pairs of the inter-costal arteries were ligated using 7-0 nylon suture (Keisei Medical Industrial Co., LTD, Tokyo, Japan), and 2 cm of the descending aorta was harvested. The graft was inserted between the renal arteries and the aortic bifurcation by standard microsurgery technique using 9-0 Nylon sutures (EthilonTM, Ethicon, Inc, Somerville, N.J.). The native abdominal aorta was left after both edges were ligated.
- CO at a concentration of 1% (10,000 parts per million; ppm) in compressed air was mixed with balanced air (21% oxygen) as described previously (Otterbein et al., Am J Physiol 276(4 Pt 1):L688–L694, 1999).
- graft donors were placed in the CO chamber two days before transplantation. Recipients were placed in the chamber immediately following transplantation and kept there 56 days. CO concentration was maintained at 250 ppm at all times.
- RT1 Brown Norway rats
- RT1 Lewis rats
- mice Male C57BL/6, p21 ⁇ / ⁇ and p53 ⁇ / ⁇ null mice were purchased from Jackson Laboratory (Bar Harbor, Me.).
- the MKK3 ( ⁇ / ⁇ ) null mice were generated as previously described (Lu et al., EMBO. J. 18:1845–1857, 1999). Mice were allowed to acclimate for one week with rodent chow and water ad libitum.
- RT-PCR was conducted after RNA isolation from the transplanted hearts by using an RNA extracting kit, according to the manufacturer's instructions (Qiagen, Chatsworth, Calif.).
- Primers used for mouse ⁇ -actin were: sense (5′-3′), CCTGACCGAGCGTGGCTACAGC (SEQ ID NO:1); antisense (3′-5′), AGCCTCCAGGGCATCGGAC (SEQ ID NO:2); and for mouse HO-1: sense (5′-3′), TCCCAGACACCGCTCCTCCAG (SEQ ID NO:3); antisense (3′-5′), GGATTTGGGGCTGCTGGTTTC (SEQ ID NO:4).
- HO-1 mRNA was detected by RT-PCR 12–24 h after transplantation and HO-1 protein 24–72 h after transplantation ( FIG. 7 ).
- Long-term graft survival did not occur when the HO inhibitor SnPPIX was administered to the donor and then to the recipient, despite treatment with CVF plus CsA. Under these conditions, all grafts were rejected in 3–7 days (Table II).
- Control treatment with FePPIX, a protoporphyrin that does not inhibit HO activity did not lead to graft rejection (Table II).
- mice hearts were transplanted into CVF plus CsA-treated rats.
- Graft recipients were treated with FePPIX or SnPPIX.
- Treatment with SnPPIX induced graft rejection 3–7 days after transplantation (p ⁇ 0.0001 as compared to rats treated with CVF plus CsA alone or with CVF plus CsA plus FePPIX).
- Statistical analyses were carried out using Fisher's exact test.
- HO activity was inhibited to basal levels, as present in naive hearts, in mouse hearts transplanted into rats treated with CVF plus CsA plus SnPPIX (32.37 ⁇ 7.23 pmol/ mg/h).
- mice hearts were transplanted into CVF plus CsA-treated rats.
- graft recipients were treated with SNPPIX with or without exposure to CO.
- Graft rejection observed in SnPPIX-treated rats was suppressed under exposure to exogenous CO (p ⁇ 0.0001 as compared to recipients treated with CVF plus CsA plus SnPPIX).
- Statistical analyses were carried out using Fisher's exact test.
- Exogenous CO may substitute for HO-1 activity in preventing graft rejection. This might work by a mechanism that involves “loading” of exogenous CO by inhalation into RBC and then delivery through the circulation into the graft at an adequate concentration. According to this theory, when endogenous HO-1 activity is being inhibited by SnPPIX, exogenous CO would mimic the effect of endogenous CO that is produced when HO-1 enzymatic activity is not impaired. Exposure of the transplant recipient to 400 ppm of exogenous CO increased carboxyl hemoglobin from 0.5 ⁇ 1.5% to 32.1 ⁇ 6.9% ( FIG. 10 ).
- Hearts transplanted into CVF plus CsA treated rats without FePPIX treatment showed significant transmural right ventricular infarctions (26.1 ⁇ 12.7%) with extensive endomyocardial and transmural left ventricular infarctions (37.6 ⁇ 15.5%) (Table IV) in a pattern that was indistinguishable from that of hearts transplanted into untreated rats (data not shown). These lesions were specific to the transplanted heart. The recipients' native hearts did not develop any infarction.
- graft recipients were treated with FePPIX or SnPPIX and exposed to CO. Results are shown as percentage of infarcted area.
- Statistical analyses were carried out using ANOVA test. An asterisk indicates significant difference as compared to all other treatments.
- HO-2, HO-1, and ferritin were detected in graft endothelial and smooth muscle cells as well as in cardiac myocytes (data not shown). There was only minimal vascular thrombosis or infiltration by host leukocytes usually associated with focal areas of infarction (data not shown). There was low but detectable P-selectin expression on the vascular endothelium (data not shown). Hearts transplanted into CVF plus CsA-treated rats, under inhibition of HO-1 activity by SnPPIX, showed similar levels of intravascular deposition of IgM and C1q as compared with control FePPIX-treated rats and no detectable IgG, C3, or C5b-9 (data not shown).
- HO-1 Generates CO that Suppresses Endothelial Cell Apoptosis
- HO-1 The antiapoptotic effect of HO-1 is mediated through its enzymatic activity because exposure of endothelial cells to SnPPIX blocked the antiapoptotic effect of HO-1 ( FIG. 12 ).
- exogenous CO 10,000 ppm
- suppressed TNF-É-mediated apoptosis suggesting that HO-1 suppresses endothelial cell apoptosis via the generation of CO ( FIG. 12 ).
- Brown Norway aortas were transplanted into Brown Norway rats (syngeneic), untreated Lewis rats (allogeneic), or Lewis rats exposed to carbon monoxide (250 ppm; allogeneic with carbon monoxide). Samples were harvested 56 days after transplantation and stained by a modified elastic tissue-masson trichrome, or by eosin hematoxylin. Brown Norway aortic segments transplanted into Lewis rats developed arteriosclerotic lesions that are consistent with those associated with chronic graft rejection (data not shown). These lesions became apparent 20–30 days after transplantation and were significantly more pronounced by 50–60 days (data not shown). For this reason, all analyses were carried out 56 days following transplantation.
- Intimal hyperplasia was inhibited in aortic grafts transplanted into recipients exposed to CO, as compared to those transplanted into recipients exposed to air, as was the accumulation of leukocytes into the adventitia (data not shown). CO had no significant effect on loss of medial SMC as compared to grafts transplanted into untreated recipients (data not shown).
- the murine 2F–2B EC line and primary bovine aortic ECs were cultured as described previously.
- ⁇ -galactosidase cDNA was cloned into the pcDNA3 vector (Invitrogen). Two vectors encoding rat HO-1 cDNA were used. The original vector encoding the full-length rat HO-1 cDNA under the control of a the ⁇ -actin enhancer/promoter ( ⁇ -actin/HO-1) has been described elsewhere. A 1.0-kbp XhoI-HindIII fragment encoding the full-length rat HO-1 cDNA was cut from the prHO-1 vector and subclones into the pcDNA3 vector to achieve expression of the HO-1 cDNA under the control of the CMV enhancer/promoter (pcDNA3/HO-1).
- the mouse Bcl-2 cDNA was cloned in the pac vector.
- p38/CSBP1 MAPK was amplified from HeLa cell cDNA by PCR and cloned into the pcDNA3/HA vector derived from pcDNA3 by inserting a DNA fragment coding for an epitope derived from the hemagglutinin protein of the human influenza virus hemagglutinin (HA; MYPYDVPDYASL).
- a dominant negative mutant of p38/CSBP1, harboring a T180A and a Y182F substitution was generated by overlap extension mutagenesis.
- Green fluorescent protein (GFP) cDNA (CLONTECH Laboratories, Inc.) was cloned into the pcDNA3-expressing vector.
- BAECs and 2F–2B ECs were transiently transfected. All experiments were carried out 24–48 h after transfection. The percentage of viable cells was assessed by evaluating the number of ⁇ -galactosidase-expressing cells that retained normal morphology. The number of random fields counted was determined to have a minimum of 200 viable transfected cells per control well. The percentage of viable cells was normalized for each DNA preparation to the number of transfected cells counted in the absence of the apoptosis-inducing agent (100% viability). All experiments were performed at least three times in duplicate.
- the recombinant HO-1 adenovirus has been described previously.
- the recombinant ⁇ -galactosidase adenovirus was a gift of Dr. Robert Gerard (University of Texas Southwestern Medical Center, Dallas, Tex.).
- Adenoviruses were produced, extracted, purified, and titrated. Confluent BAECs were infected with a multiplicity of infection of 200 PFU/cell.
- HO-1 was detected using a rabbit anti-human HO-1 polyclonal antibody (StressGen Biotechnologies).
- Vasodilatator-stimulated phosphoprotein (VASP) was detected using a rabbit anti-human VASP polyclonal antibody (Calbiochem-Novabiochem).
- ERK-1 and -2 Total and activated/phosphorylated forms of extracellular signal-regulated kinases (ERK-1 and -2), c-Jun NH 2 -terminal kinases (JNK-1, -2, and -3), and p38 MAPK were detected using rabbit polyclonal antibodies directed against the total or phosphorylated forms of these MAPKs, according to the manufacturer's suggestions (New England Biolabs, Inc.).
- ⁇ -Tubulin was detected using anti-human ⁇ -tubulin monoclonal antibody (Boehringer).
- Primary antibodies were detected using horseradish peroxidase-conjugated donkey anti-rabbit or goat anti-mouse IgG secondary antibodies (Pierce Chemical Co.).
- Peroxidase was visualized using the enhanced chemiluminescence assay (Amersham Pharmacia Biotech) according to the manufacturer's instructions, and stored in the form of photoradiographs (BiomaxTM MS; Eastman Kodak Co.). Digital images were obtained using an image scanner (Arcus II; Agfa) equipped with FotoLookTM and Photoshop® software. The amount of phosphorylated ERK, JNK, and p38 MAPK was quantified using ImageQuant® software (Molecular Dynamics). When indicated, membranes were stripped (62.5 mM Tris-HCl, pH 6.8, 2% SDS, and 100 mM ⁇ -mercaptoethanol, 30 min, 50° C.). Phosphorylated ERK, JNK, and p38 MAPK were normalized to the total amount of total ERK, JNK, and p38 MAPK detected in the same membrane.
- 2F–2B ECs were transfected with the GFP expression plasmid and harvested 24 h after transfection by trypsin digestion (0.05% in PBS). ECs were washed in PBS, pH 7.2, 5% FCS, and fluorescent labeling was evaluated using a FACSortTM equipped with CELLQuestTM software (Becton Dickinson).
- Actinomycin D (Act.D; Sigma-Aldrich) was dissolved in PBS and added to the culture medium 24 h after transfection.
- the Act.D concentration used corresponded to the optimal concentration necessary to sensitize ECs to TNF- ⁇ mediated apoptosis, e.g., 10 ⁇ g/ml for 2F–2B ECs and 0.1 ⁇ g/ml for BAECs.
- EC apoptosis was induced by etoposide (200 ⁇ M, 8 h; Calbiochem-Novabiochem) or by serum deprivation (0.1% FCS for 24 h).
- the iron chelator deferoxamine mesylate (DFO; Sigma-Aldrich) was dissolved in water and added to culture medium (1–100 ⁇ M) 1 h before the induction of apoptosis.
- Hemoglobin (Hb; Sigma-Aldrich) was dissolved (1 mM) in PBS, 10 mM Na 2 S 2 O 4 , dialyzed against PBS (2 h, 4° C., 1:800 dilution), and added to the culture medium (1–100 ⁇ M) 6 h after transfection.
- the guanylcyclase inhibitor 1H(1,2,4)oxadiazolo(4,3)quinoxalin-1 was dissolved in DMSO (Sigma-Aldrich) and added to the culture medium (10–100 ⁇ M) 6 h after transfection.
- Iron protoporphyrin ([FePP]/heme), cobalt protoporphyrin (CoPPIX), and tin protoporphyrin (SnPPIX; all from Porphyrin Products, Inc.) were dissolved (10 mM) in 100 mM NaOH and held at ⁇ 20° C. until use.
- Metalloporphyrins were added to the culture medium (50 ⁇ M) 6 h after transfection.
- the cGMP analogue 8-bromo-cGMP sodium salt (8-Br-cGMP; Sigma-Aldrich) was dissolved in water and added to the culture medium (10–100 gM) 30 min before the induction of apoptosis.
- Human recombinant TNF- (R&D Systems) was dissolved in PBS and 1% BSA, and added to the culture medium (10–100 ng/ml) 24 h after transfection.
- the p38 MAPK inhibitor pyridinyl imidazol SB203580 was dissolved in DMSO and added to the culture medium (5–20 ⁇ M) 6 h after transfection.
- Cells were exposed to compressed air from a compressed air tank or varying concentrations of CO (250 and 10,000 ppm).
- TNF- ⁇ induces apoptosis of cultured ECs when transcriptional activity is inhibited by Act.D.
- the data in FIGS. 13A–D were generated as follows: (A) 2F–2B ECs were transfected with a GFP-expressing plasmid and monitored for GFP expression by flow cytometry.
- the percentage of transfected ECs was assessed by measuring fluorescence intensity in ECs transfected with control (pcDNA3; filled histogram) versus GFP (open histogram) expression plasmids; (B) ECs were cotransfected with ⁇ -galactosidase plus control (pcDNA3) or HO-1 ( ⁇ -actin/HO-1) expression vectors. EC apoptosis was induced by TNF- ⁇ plus Act.D and apoptosis of ⁇ -galactosidase-transfected ECs was quantified. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- Results shown are the mean ⁇ SD from duplicate wells taken from 1 representative experiment out of 10;
- C HO-1 expression was detected in BAECs by Western blot. No Tr, nontransfected. NT, nontreated;
- D 2F–2B ECs were cotransfected with ⁇ -galactosidase plus control (pcDNA3) or HO-1 ( ⁇ -actin/HO-1) expression vectors. Gray bars represent untreated ECs and black bars represent ECs treated with etoposide (200 ⁇ M, 8 h) or subjected to serum deprivation (0.1% FCS for 24 h). Results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three independent experiments. Similar results were obtained using BAECs.
- ECs were transfected with a GFP-expressing plasmid and the percentage of GFP-expressing ECs was evaluated by flow cytometry. As illustrated in FIG. 13 , 45% of ECs expressed the GFP protein 24 h after transfection. We then tested whether transfection of HO-1 would prevent ECs from undergoing TNF- ⁇ mediated apoptosis. To do so, ECs were cotransfected with HO-1 and ⁇ -galactosidase and apoptosis was evaluated by counting the number of viable ⁇ -galactosidase-expressing ECs.
- TNF- ⁇ plus Act.D induced apoptosis of control ECs transfected with the pcDNA3 60–70% apoptotic ECs.
- Overexpression of HO-1 prevented EC apoptosis (5–10% apoptotic ECs; FIG. 13 ).
- the expression of HO-1 was confirmed by Western blot ( FIG. 13 ).
- Overexpression of HO-1 also prevented EC apoptosis induced by other proapoptotic stimuli such as etoposide or serum deprivation, which is in keeping with similar observations in 293 cells.
- FIG. 14 The antiapoptotic effect of HO-1 was dose dependent in that increasing levels of HO-1 expression resulted in increased protection from TNF- ⁇ plus Act.D-mediated apoptosis ( FIG. 14 ).
- the data in FIGS. 14A–B were generated as follows: (A) 2F–2B ECs were cotransfected with increasing doses of HO-1 expression vector ( ⁇ -actin/HO-1). EC apoptosis was induced by TNF- ⁇ plus Act.D. Results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three. Similar results were obtained using BAECs; (B) The expression of HO-1 was detected in BAECs by Western blot.
- FIGS. 15A–B The data in FIGS. 15A–B were generated as follows: (A) 2F–2B ECs were cotransfected with ⁇ -galactosidase plus pcDNA3, HO-1 ( ⁇ -actin/HO-1), or bcl-2 expression vectors. Cells were either left untreated (Control) or treated with the inhibitor of HO enzymatic activity SnPPIX. CoPPIX, a protoporphyrin that does not inhibit HO enzymatic activity, was used as a control treatment.
- Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. Results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- B 2F–2B ECs were transfected with ⁇ -galactosidase plus pcDNA3 expression vectors. ECs were either left untreated (Control) or were treated with SnPPIX and CoPPIX as in A. The results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three. When HO-1 activity was blocked by SnPPIX, HO-1 was no longer able to prevent EC apoptosis ( FIG.
- HO-1 enzymatic activity is needed for its antiapoptotic effect, this suggests that this antiapoptotic effect is mediated through one or more end products of heme catabolism by HO-1, i.e., bilirubin, iron, and/or CO.
- CO would account for the antiapoptotic effect of HO-1.
- ECs were transiently transfected with HO-1 and treated with Hb to scavenge CO ( FIG. 16 ). The data in FIG. 16 were generated as follows: 2F–2B ECs were cotransfected with ⁇ -galactosidase plus control (pcDNA3), HO-1 ( ⁇ -actin/HO-1), or bcl-2 expression vectors.
- ECs were either left untreated (0) or were treated with increasing concentrations of Hb. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. The results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of four. Under these conditions, the antiapoptotic effect of HO-1 was suppressed ( FIG. 16 ). The ability of Hb to block the antiapoptotic effect of HO-1 was dose dependent, in that increasing concentrations of Hb (3–50 ⁇ M) decreased the ability of HO-1 to prevent EC apoptosis ( FIG. 16 ). Hb did not impair the antiapoptotic effect of bcl-2 ( FIG. 16 ), nor did it sensitize control ECs (pcDNA3) to apoptosis ( FIG. 16 ).
- Exogenous CO can Substitute for HO-1 in Preventing EC Apoptosis
- FIGS. 17A–C show that this is the case.
- the data in FIGS. 17A–C were generated as follows: (A) 2F–2B ECs were transfected with a ⁇ -galactosidase expression vector and exposed to exogenous CO. Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D. (B) 2F–2B ECs were transfected with a ⁇ -galactosidase expression vector and exposed to exogenous CO (10,000 ppm) with or without Hb.
- Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- C 2F–2B ECs were cotransfected with ⁇ -galactosidase and HO-1 ( ⁇ -actin/HO-1) expression vectors. Where indicated (+), HO-1 enzymatic activity was inhibited by SnPPIX and/or exposed to exogenous CO.
- Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. Results shown (A, B, and C) are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- ECs that express HO-1 may generate sufficient levels of CO to protect neighboring ECs that do not express HO-1 from undergoing apoptosis.
- ECs were transfected with control (pcDNA3) or HO-1 expression vectors and cocultured with ⁇ -galactosidase-transfected ECs ( FIG. 18 ).
- the data in FIG. 18 were generated as follows: 2F–2B ECs were transfected with control (pcDNA3; I and II) or HO-1 (III) expression vectors.
- ECs 16 h after transfection, ECs were harvested, washed, and cocultured at a ratio of 1:1 with ECs transfected with ⁇ -galactosidase (I and II) or with ⁇ -galactosidase plus HO-1 (III). Cocultures were maintained for an additional 24 h before induction of apoptosis by TNF- ⁇ plus Act.D. The percentage of survival was evaluated by counting the number of ⁇ -galactosidase-positive cells that retained normal morphology. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. Results shown are the mean ⁇ SD from duplicates taken from one representative experiment out of three.
- FIGS. 19A–B The data illustrated in FIGS. 19A–B suggest that this is the case.
- the data in FIGS. 19A–B were generated as follows: (A) 2F–2B ECs were cotransfected with a ⁇ -galactosidase expression vector and exposed to FePP. Apoptosis was induced by TNF- ⁇ and Act.D. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. The results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- 20A–C were generated as follows: (A) 2F–2B ECs were transfected with a ⁇ -galactosidase expression vector and exposed to DFO. Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D. (B) 2F–2B ECs were cotransfected as described above in A. Where indicated (+), HO-1 enzymatic activity was inhibited by SnPPIX and iron was chelated by DFO, as described above in A. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. (C) 2F–2B ECs were cotransfected as described above in A.
- FIG. 21 The data in FIG. 21 were generated as follows: 2F–2B ECs were cotransfected with ⁇ -galactosidase and HO-1 ( ⁇ -actin/HO-1) expression vectors. Where indicated (+), cells were treated with the inhibitor of HO enzymatic activity SnPPIX. ECs were exposed to CO (250 ppm) and to the iron chelator DFO. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- the Antiapoptotic Effect of HO-1 is not Mediated by Guanylcyclase Activation or cGMP Generation
- HO-1-transfected cells were exposed to increasing doses of the guanylcyclase inhibitor ODQ.
- Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- the results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- Activation of guanylcyclase was monitored in BAECs by analyzing the phosphorylation of VASP.
- P-VASP (50 kD) and VASP (46 kD) are the phosphorylated and nonphosphorylated forms of VASP, respectively.
- (C) 2F–2B ECs were transfected with ⁇ -galactosidase or with ⁇ -galactosidase plus HO-1 ( ⁇ -actin/HO-1) expression vectors as described above in A. Where indicated, ECs were exposed to the cGMP analogue 8-Br-cGMP, as described above. Gray bars represent ECs treated with Act.D and black bars represent ECs treated with TNF- ⁇ plus Act.D. The results shown are the mean ⁇ SD from duplicate wells taken from one representative experiment out of three.
- D Phosphorylation of VASP was analyzed by Western blot as described above in B. N.T., nontreated.
- HO-1 in ECs did not result in a detectable increase of cGMP-related functions as illustrated by the absence of VASP phosphorylation, a protein phosphorylated by cyclic nucleotide-dependent protein kinases (protein kinase G- ⁇ / ⁇ ; FIG. 22 ). This finding is in keeping with that reported by others. Inhibition of guanylcyclase activity by ODQ did not suppress the antiapoptotic effects of HO-1, and the cGMP analogue 8-Br-cGMP failed to suppress EC apoptosis ( FIG. 22 ).
- That 8-Br-cGMP acted as a cGMP analogue was shown by its ability to induce VASP phosphorylation ( FIG. 22 ). That ODQ was efficient in suppressing guanylcyclase activity in ECs was shown by its ability to prevent constitutive VASP phosphorylation in 2F–2B ECs (data not shown).
- HO-1 Increases TNF- ⁇ -mediated Activation of p38 MAPK in ECs
- FIGS. 23A–B The data in FIG. 23 were generated as follows: (A) BAECs were stimulated with TNF- ⁇ (10 ng/ml; time 0) and MAPK phosphorylation was monitored by Western blot (0, 5, 15, 30, 60, and 120 min after TNF- ⁇ stimulation) using antibodies directed against the phosphorylated forms of each MAPK. One single membrane was used for all the stainings shown. Experiments were repeated three times with virtually identical results. n.s., nonspecific band.
- FIGS. 24A–B were generated as follows: (A) BAECs were either nontransduced (NT), transduced with a ⁇ -galactosidase ( ⁇ gal.) adenovirus, or transduced with HO-1 recombinant adenovirus, and were left untreated ( ⁇ ) or treated (+) with TNF- ⁇ (10 ng/ml for 15 min). p38 MAPK phosphorylation was monitored by Western blot using antibodies directed against the phosphorylated forms of each MAPK. Results are presented as fold induction of MAPK activation by TNF- ⁇ in arbitrary units (A.U.), compared with the amount of induction at time 0, before TNF- ⁇ stimulation.
- BAECs were stimulated (+) or not ( ⁇ ) by TNF- ⁇ (10 ng/ml, 30 min) in the presence or absence of CO (10,000 ppm). Phosphorylation of p38 MAPK was quantified as in A. The results are presented as fold induction of MAPK activation by TNF- ⁇ in arbitrary units (A.U.). Recombinant adenovirus mediated overexpression of HO-1 potentiated the ability of TNF- ⁇ to activate p38 MAPK ( FIG. 24 ), but not to activate JNK (data not shown). Overexpression of ⁇ -galactosidase had no detectable effect on the activation of either p38 MAPK or JNK by TNF- ⁇ . Exposure of ECs to exogenous CO activated p38 MAPK even in the absence of TNF- ⁇ ( FIG. 24 ).
- FIGS. 25A–D The data in FIGS. 25A–D were generated as follows: A) 2F–2B ECs were cotransfected with ⁇ -galactosidase, control (pcDNA3), or HO-1 ( ⁇ -actin/HO-1) expression vectors. Where indicated, ECs were treated with the p38 kinase inhibitor SB203580. Gray bars represent ECs treated with Act.D alone and black bars represent ECs treated with TNF- ⁇ plus Act.D.
- BAECs were transfected with a control (pcDNA3) vector and stimulated with TNF- ⁇ in the presence ( ⁇ ) or absence ( ⁇ ) of the p38 kinase inhibitor SB203580 (20 ⁇ M).
- MAPK phosphorylation was monitored by Western blot (0, 5, 15, 30, 60, and 120 min after TNF- ⁇ stimulation) using antibodies directed against the phosphorylated forms of each MAPK.
- the following example illustrates protocols for use in treating a donor, and organ, and a recipient with carbon monoxide during a transplantation procedure. Any one or more of the following procedures may be used in a given transplantation procedure.
- the donor Prior to harvesting an organ or tissue, the donor can be treated with inhaled carbon monoxide (250 ppm) for one hour. Treatment can be administered at doses varying from 10 ppm to 1000 ppm for times varying from one hour to six hours, or for the entire period from the moment when it becomes possible to treat a brain-dead (cadaver) donor to the time the organ is removed. Treatment should start as soon as possible following the declaration that brain death is present. In some applications, it may be desirable to begin treatment before brain death.
- inhaled carbon monoxide 250 ppm
- Treatment can be administered at doses varying from 10 ppm to 1000 ppm for times varying from one hour to six hours, or for the entire period from the moment when it becomes possible to treat a brain-dead (cadaver) donor to the time the organ is removed. Treatment should start as soon as possible following the declaration that brain death is present. In some applications, it may be desirable to begin treatment before brain death.
- the live animal can be treated with relatively high levels of inhaled carbon monoxide, as desired, so long as the carboxyhemoglobin so produced does not compromise the viability and function of the organ to be transplanted.
- levels greater than 500 ppm e.g., 1000 ppm or higher, and up to 10,000 ppm, particularly for brief times.
- an organ Before an organ is harvested from a donor, it can be flushed with a solution, e.g., a buffer or medium, without red blood cells while it is still in the donor.
- a solution e.g., a buffer or medium
- the intent is to flush the organ with a solution saturated with carbon monoxide and maintained in a carbon monoxide atmosphere so that the carbon monoxide content remains at saturation. Flushing can take place for a time period of at least 10 minutes, e.g., 1 hour, several hours, or longer.
- the solution should ideally deliver the highest concentration of carbon monoxide possible to the cells of the organ.
- the organ or tissue can be preserved in a medium that includes carbon monoxide from the time it is removed from the donor to the time it is transplanted to the recipient. This can be performed by maintaining the organ or tissue in the medium comprising CO, or by perfusing it with such a medium. Since this occurs ex vivo rather than in an animal, very high concentrations of CO gas can be used (e.g., 10,000 ppm) to keep the medium saturated with CO.
- the recipient can be treated with carbon monoxide. Treatment can begin on the day of transplantation at least 30 minutes before surgery begins. Alternatively, it could begin at least 30 minutes before re-perfusion of the organ in the recipient. It can be continued for at least 30 minutes, e.g., 1 hour.
- Carbon monoxide doses between 10 ppm and 3000 ppm can be delivered for varying times, e.g., minutes or hours, and can be administered on the day of and on days following transplantation.
- a recipient can inhale a concentration of carbon monoxide, e.g., 3000 ppm, for three consecutive 10 second breath holds.
- the recipient can inhale, say 200 ppm for an extended time, such as 20 days.
- Carboxyhemoglobin concentrations can be utilized as a guide for appropriate administration of carbon monoxide to a patient. Usually, treatments for recipients should not raise carboxyhemoglobin levels above those considered to pose an acceptable risk for a patient in need of a transplant.
Abstract
Description
TABLE I |
Induction of HO-1 in Donors and Recipients |
Leads to Prolonged Islet Graft Survival |
No. of | Rejection/ | |||
Treatment | Islets | Rejection day | Mean ± | Total |
CoPP | ||||
20 mg/ | 350–400 | 17, 33, 33, 48 | 44.85 ± 17.81 | 4/7 |
kg × 5 | >58 × 2, | |||
>67 × 1 | ||||
|
350–400 | 30, 30, >51 × 2 | 40.5 ± 12.12 | 2/4 |
kg × 10 | ||||
Control | 350–400 | 8, 8, 15, 15, | 15.71 ± 6.65 | 7/7 |
16, 22, 26 | ||||
TABLE II |
Inhibition of HO-1 activity by SnPPIX precipitates graft rejection. |
Treatment | Survival Time | ||
CVF + CsA | >50 (n = 8) | ||
CVF + CsA + FePPIX | >50 (n = 4) | ||
CVF + CsA + |
3, 4, 5 (n = 2); 6 (n = 4); 7 (n = 2) | ||
TABLE III |
Exogenous CO fully substitutes for HO-1 in suppressing graft rejection |
Treatment | Survival Time (days) |
CVF + CsA + |
3, 4, 5, (n = 2); 6 (n = 4); 7 (n = 2) |
CVF + CsA + SnPPIX + CO | >50 (n = 6) |
TABLE IV |
Morphometric analysis |
Treatment | Right Ventricle | Left Ventricle |
CVF + CsA | 4.5 ± 4.9 | 0.7 ± 2.1 |
CVF + CsA + FePPIX | 12.2 ± 9.5 | 0.7 ± 1.3 |
CVF + CsA + SnPPIX | 26.1 ± 12.7* | 37.6 ± 15.5* |
CVF + CsA + SnPPIX + CO | 8.4 ± 5.3 | 1.8 ± 3.4 |
Claims (54)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/177,930 US7238469B2 (en) | 2001-06-21 | 2002-06-21 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US11/401,722 US20070202083A1 (en) | 2001-06-21 | 2006-04-10 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30028901P | 2001-06-21 | 2001-06-21 | |
US33434001P | 2001-11-29 | 2001-11-29 | |
US33797401P | 2001-12-07 | 2001-12-07 | |
US10/177,930 US7238469B2 (en) | 2001-06-21 | 2002-06-21 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/401,722 Division US20070202083A1 (en) | 2001-06-21 | 2006-04-10 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030039638A1 US20030039638A1 (en) | 2003-02-27 |
US7238469B2 true US7238469B2 (en) | 2007-07-03 |
Family
ID=27404726
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/177,930 Expired - Lifetime US7238469B2 (en) | 2001-06-21 | 2002-06-21 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US11/401,722 Abandoned US20070202083A1 (en) | 2001-06-21 | 2006-04-10 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/401,722 Abandoned US20070202083A1 (en) | 2001-06-21 | 2006-04-10 | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
Country Status (26)
Country | Link |
---|---|
US (2) | US7238469B2 (en) |
EP (2) | EP1404811B1 (en) |
JP (1) | JP4521183B2 (en) |
KR (1) | KR20040032115A (en) |
CN (1) | CN100502650C (en) |
AT (1) | ATE413883T1 (en) |
AU (2) | AU2002318377B2 (en) |
BG (1) | BG108492A (en) |
BR (1) | BR0210599A (en) |
CA (1) | CA2451266A1 (en) |
CY (1) | CY1108798T1 (en) |
CZ (1) | CZ20033448A3 (en) |
DE (1) | DE60229848D1 (en) |
DK (1) | DK1404811T3 (en) |
ES (1) | ES2316583T3 (en) |
HK (1) | HK1067380A1 (en) |
HU (1) | HUP0400371A3 (en) |
MX (1) | MXPA03012031A (en) |
NO (1) | NO20035637L (en) |
NZ (1) | NZ562962A (en) |
PL (1) | PL367544A1 (en) |
PT (1) | PT1404811E (en) |
SG (1) | SG147305A1 (en) |
SI (1) | SI1404811T1 (en) |
SK (1) | SK15942003A3 (en) |
WO (1) | WO2003000114A2 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020155166A1 (en) * | 1999-04-01 | 2002-10-24 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US20030219497A1 (en) * | 2002-04-15 | 2003-11-27 | Otterbein Leo E. | Methods of treating ileus |
US20040005367A1 (en) * | 2002-04-15 | 2004-01-08 | Otterbein Leo E. | Methods of treating necrotizing enterocolitis |
US20040052866A1 (en) * | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
US20040228930A1 (en) * | 2002-11-07 | 2004-11-18 | Billiar Timothy R. | Treatment for hemorrhagic shock |
US20040258772A1 (en) * | 2002-06-05 | 2004-12-23 | Otterbein Leo E. | Methods of treating angiogenesis, tumor growth, and metastasis |
US20050048133A1 (en) * | 1996-09-27 | 2005-03-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US20060003922A1 (en) * | 2002-04-15 | 2006-01-05 | Bach Fritz H | Spinner preparation machine and cavity resonator |
WO2013022946A1 (en) | 2011-08-09 | 2013-02-14 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating dna damage |
US8927750B2 (en) | 2011-02-04 | 2015-01-06 | Universitaet Zu Koeln | Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules |
US9629358B2 (en) | 2013-03-15 | 2017-04-25 | Mallinckrodt Hospital Products IP Limited | Administration and monitoring of nitric oxide in ex vivo fluids |
US9789133B2 (en) | 2014-04-15 | 2017-10-17 | Proterris, Inc. | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity |
WO2019040921A1 (en) * | 2017-08-25 | 2019-02-28 | Mallinckrodt Hospital Products IP Limited | Methods to improve organ viability |
US10667510B2 (en) | 2013-03-15 | 2020-06-02 | Mallinckrodt Hospital Products IP Limited | Administration and monitoring of nitric oxide in ex vivo fluids |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0111872D0 (en) | 2001-05-15 | 2001-07-04 | Northwick Park Inst For Medica | Therapeutic agents and methods |
EP1404811B1 (en) * | 2001-06-21 | 2008-11-12 | Beth Israel Deaconess Medical Center, Inc. | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US7968605B2 (en) * | 2002-02-04 | 2011-06-28 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
EP2319518A1 (en) * | 2002-02-04 | 2011-05-11 | ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. | Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
US20080026984A1 (en) * | 2002-02-04 | 2008-01-31 | Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof |
CN100393323C (en) | 2002-02-13 | 2008-06-11 | 贝思·伊斯雷尔·迪科尼斯医药中心 | Methods of treating vascular disease |
GB2395432B (en) * | 2002-11-20 | 2005-09-14 | Northwick Park Inst For Medica | Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs |
AU2004285477A1 (en) * | 2003-10-22 | 2005-05-12 | Fred Hutchinson Cancer Research Center | Methods, compositions and devices for inducing stasis in tissues and organs |
EP1552840A1 (en) * | 2004-01-07 | 2005-07-13 | Aga Ab | Use of a xenon/carbon monoxide mixture for the protection of cells |
CA2600927C (en) | 2005-03-07 | 2017-04-18 | Sangart, Inc. | Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers |
EP1937059A2 (en) * | 2005-07-27 | 2008-07-02 | University Of North Carolina At Charlotte | Composition and method for the restoration and preservation of transplant organs procured from dcd donors |
WO2007073225A1 (en) * | 2005-12-20 | 2007-06-28 | Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda. | Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases |
WO2007073226A1 (en) * | 2005-12-20 | 2007-06-28 | Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda | Method for treating a mammal by administration of a compound having the ability to release co |
GB0601394D0 (en) | 2006-01-24 | 2006-03-01 | Hemocorm Ltd | Therapeutic delivery of carbon monoxide |
WO2008063868A2 (en) | 2006-11-07 | 2008-05-29 | The General Hospital Corporation | Attenuation of vasoactive oxygen carrier-induced vasoconstriction |
CA2763111C (en) | 2009-05-27 | 2019-09-24 | Ino Therapeutics Llc | Devices and methods for engaging indexed valve and pressurized canister assembly with collar and for linear actuation by plunger assembly into fluid communication with device for regulating drug delivery |
JP2011010865A (en) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | Method of treating term and near-term neonate having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension |
ES2742829T3 (en) | 2011-01-14 | 2020-02-17 | Los Angeles Childrens Hospital | Carbon monoxide solution for the treatment of a disease, including sickle cell anemia |
CA2830420A1 (en) | 2011-03-16 | 2012-09-20 | Mayo Foundation For Medical Education And Research | Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations |
JP5978291B2 (en) | 2011-04-19 | 2016-08-24 | アルファーマ インコーポレイテッドAlfama,Inc. | Carbon monoxide releasing molecules and uses thereof |
JP2014520113A (en) * | 2011-06-10 | 2014-08-21 | ゲノ エルエルシー | Nitric oxide (NO) pressurized container |
WO2013013179A1 (en) | 2011-07-21 | 2013-01-24 | Alfama, Inc. | Ruthenium carbon monoxide releasing molecules and uses thereof |
CN105288599A (en) * | 2015-10-22 | 2016-02-03 | 徐州医学院 | Application of heme oxygenase-2 in preparing preparations inhibiting organ transplantation immune rejection |
EP3524290A1 (en) | 2018-02-09 | 2019-08-14 | Julius-Maximilians-Universitaet Wuerzburg | Method and system for monitoring carbon monoxide (co) administration to ex-vivo fluids |
CN116076484A (en) * | 2022-11-30 | 2023-05-09 | 武汉大学 | Low-temperature oxygen-carrying mechanical perfusion fluid for repairing kidney injury and application thereof |
Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4264739A (en) | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
JPS5679957A (en) | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US4923817A (en) | 1987-11-23 | 1990-05-08 | "Immuno" Aktiengesellschaft Fur Chemisch-Medizinische | Fermenter for culturing cell cultures |
US5084380A (en) | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5240912A (en) | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US5293875A (en) | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
WO1994022482A1 (en) | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5449665A (en) | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
WO1995035105A1 (en) | 1994-06-18 | 1995-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system with active substances constituting sources of carbon monoxide |
US5664563A (en) | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
WO1998008523A1 (en) | 1996-08-27 | 1998-03-05 | Messer Griesheim Gmbh | Hydrogenous medicament |
US5731326A (en) | 1995-06-30 | 1998-03-24 | Zymogenetics, Inc. | PDGF antagonists II |
WO1998013058A1 (en) | 1996-09-27 | 1998-04-02 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US5763431A (en) | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
US5792325A (en) | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
US5885621A (en) | 1996-04-05 | 1999-03-23 | The General Hospital Corporation | Treatment of a hemoglobinopathy |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
WO1999047512A1 (en) | 1998-03-16 | 1999-09-23 | Colgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
WO1999049880A1 (en) | 1998-04-01 | 1999-10-07 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US6066333A (en) | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
US6203991B1 (en) | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US6313144B1 (en) | 1995-06-07 | 2001-11-06 | Sepracor, Inc. | Compositions of optically pure (−) norcisapride |
US6316403B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
WO2002009731A1 (en) | 2000-07-27 | 2002-02-07 | L'air Liquide Sante (International) | Use of co for treating inflammation of upper airways or bronchi |
FR2816212A1 (en) | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation |
WO2002078684A2 (en) | 2001-03-30 | 2002-10-10 | Sangstat Medical Corporation | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
WO2002092075A2 (en) | 2001-05-15 | 2002-11-21 | Northwick Park Institute For Medical Research | Therapeutic delivery of carbon monoxide |
WO2003000114A2 (en) | 2001-06-21 | 2003-01-03 | Beth Israel Deaconess Medical Center | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US20030009127A1 (en) | 2001-05-25 | 2003-01-09 | Trescony Paul V. | Implantable medical device with controllable gaseous agent release system |
US20040067261A1 (en) | 2002-02-04 | 2004-04-08 | Werner Haas | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
US20040197271A1 (en) | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
US20050048133A1 (en) * | 1996-09-27 | 2005-03-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US20050250688A1 (en) | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
WO1994018954A1 (en) * | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
US6063407A (en) | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
FR2735382B1 (en) * | 1995-06-15 | 1997-07-25 | Air Liquide | CARBON MONOXIDE PRODUCTION PLANT INCORPORATING A CRYOGENIC SEPARATION UNIT |
US5869538A (en) * | 1996-11-26 | 1999-02-09 | Research Foundation Of State University Of New York | Method for enhancing transport of gases to tissues |
FR2757259B1 (en) * | 1996-12-18 | 1999-03-05 | Valeo Thermique Moteur Sa | IMPROVED METAL FIN FOR A HEAT EXCHANGER, PARTICULARLY FOR A MOTOR VEHICLE |
US5912019A (en) * | 1997-02-07 | 1999-06-15 | Musc Foundation For Research Development | Compounds for reducing ischemia/reperfusion injury |
US7678390B2 (en) * | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7632803B2 (en) * | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
US6558825B1 (en) * | 2000-05-12 | 2003-05-06 | Reveo, Inc. | Fuel containment and recycling system |
CN100393323C (en) * | 2002-02-13 | 2008-06-11 | 贝思·伊斯雷尔·迪科尼斯医药中心 | Methods of treating vascular disease |
JP4585765B2 (en) * | 2002-04-15 | 2010-11-24 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | How to treat necrotizing enterocolitis |
WO2003088923A2 (en) * | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
AU2003226366A1 (en) * | 2002-04-15 | 2003-11-03 | Beth Israel Deaconess Medical Center | Use of heme oxygenase-1 and products of heme degradation |
WO2003096977A2 (en) * | 2002-05-17 | 2003-11-27 | Yale University | Methods of treating hepatitis |
EA200401622A1 (en) * | 2002-06-05 | 2005-06-30 | Йейл Юниверсити | METHODS OF TREATING ANGIOGENESIS, GROWTH OF TUMORS AND METASTASES |
PL375161A1 (en) * | 2002-06-21 | 2005-11-28 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
JP2006514621A (en) * | 2002-11-07 | 2006-05-11 | ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | Treatment of hemorrhagic shock |
WO2005077005A2 (en) * | 2004-02-04 | 2005-08-25 | The General Hospital Corporation | Enhancing the effectiveness of an inhaled therapeutic gas |
-
2002
- 2002-06-21 EP EP02747932A patent/EP1404811B1/en not_active Revoked
- 2002-06-21 AU AU2002318377A patent/AU2002318377B2/en not_active Ceased
- 2002-06-21 PT PT02747932T patent/PT1404811E/en unknown
- 2002-06-21 BR BR0210599-3A patent/BR0210599A/en not_active IP Right Cessation
- 2002-06-21 ES ES02747932T patent/ES2316583T3/en not_active Expired - Lifetime
- 2002-06-21 SK SK1594-2003A patent/SK15942003A3/en not_active Application Discontinuation
- 2002-06-21 DE DE60229848T patent/DE60229848D1/en not_active Expired - Lifetime
- 2002-06-21 JP JP2003506568A patent/JP4521183B2/en not_active Expired - Fee Related
- 2002-06-21 SG SG200601852-7A patent/SG147305A1/en unknown
- 2002-06-21 EP EP08168801A patent/EP2033514A3/en not_active Withdrawn
- 2002-06-21 NZ NZ562962A patent/NZ562962A/en not_active IP Right Cessation
- 2002-06-21 CN CNB028163443A patent/CN100502650C/en not_active Expired - Fee Related
- 2002-06-21 US US10/177,930 patent/US7238469B2/en not_active Expired - Lifetime
- 2002-06-21 CA CA002451266A patent/CA2451266A1/en not_active Abandoned
- 2002-06-21 SI SI200230772T patent/SI1404811T1/en unknown
- 2002-06-21 MX MXPA03012031A patent/MXPA03012031A/en active IP Right Grant
- 2002-06-21 KR KR10-2003-7016702A patent/KR20040032115A/en active IP Right Grant
- 2002-06-21 DK DK02747932T patent/DK1404811T3/en active
- 2002-06-21 CZ CZ20033448A patent/CZ20033448A3/en unknown
- 2002-06-21 HU HU0400371A patent/HUP0400371A3/en unknown
- 2002-06-21 WO PCT/US2002/019687 patent/WO2003000114A2/en active Application Filing
- 2002-06-21 AT AT02747932T patent/ATE413883T1/en not_active IP Right Cessation
- 2002-06-21 PL PL02367544A patent/PL367544A1/en unknown
-
2003
- 2003-12-17 NO NO20035637A patent/NO20035637L/en not_active Application Discontinuation
- 2003-12-22 BG BG108492A patent/BG108492A/en unknown
-
2004
- 2004-09-10 HK HK04107560.1A patent/HK1067380A1/en not_active IP Right Cessation
-
2006
- 2006-04-10 US US11/401,722 patent/US20070202083A1/en not_active Abandoned
-
2008
- 2008-09-18 AU AU2008221551A patent/AU2008221551A1/en not_active Ceased
-
2009
- 2009-02-09 CY CY20091100145T patent/CY1108798T1/en unknown
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053590A (en) | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
US4264739A (en) | 1979-01-05 | 1981-04-28 | Merck & Co., Inc. | Sparger for cell culture system |
JPS5679957A (en) | 1979-12-05 | 1981-06-30 | Sogo Seibutsu Igaku Kenkyusho:Kk | Erucinia enterocolitica polysaccharide sensitizing blood cell and method of detecting erucinia enterocolitica polysaccharide antibody using this |
US5240912A (en) | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
US5084380A (en) | 1985-01-29 | 1992-01-28 | Applied Biotechnology | Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins |
US5449665A (en) | 1985-09-24 | 1995-09-12 | Item Development Aktiebolag | Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty |
US4923817A (en) | 1987-11-23 | 1990-05-08 | "Immuno" Aktiengesellschaft Fur Chemisch-Medizinische | Fermenter for culturing cell cultures |
US5180366A (en) | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5792325A (en) | 1990-11-15 | 1998-08-11 | Richardson, Jr.; William H. | Electric arc material processing system |
US5293875A (en) | 1992-06-16 | 1994-03-15 | Natus Medical Incorporated | In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods |
WO1994022482A1 (en) | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
US5763431A (en) | 1993-08-20 | 1998-06-09 | Jackson; Meyer B. | Method for regulating neuropeptide hormone secretion |
WO1995035105A1 (en) | 1994-06-18 | 1995-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system with active substances constituting sources of carbon monoxide |
US5882674A (en) | 1994-06-18 | 1999-03-16 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system comprising active substances representing carbon monoxide sources |
US5476764A (en) | 1994-09-16 | 1995-12-19 | The Regents Of The University Of California | Method using CO for extending the useful shelf-life of refrigerated red blood cells |
US6066333A (en) | 1994-09-22 | 2000-05-23 | William Harvey Research Limited | Pharmaceutical control of inflammation |
US5664563A (en) | 1994-12-09 | 1997-09-09 | Cardiopulmonary Corporation | Pneumatic system |
US5914316A (en) | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
US6313144B1 (en) | 1995-06-07 | 2001-11-06 | Sepracor, Inc. | Compositions of optically pure (−) norcisapride |
US5731326A (en) | 1995-06-30 | 1998-03-24 | Zymogenetics, Inc. | PDGF antagonists II |
US5885621A (en) | 1996-04-05 | 1999-03-23 | The General Hospital Corporation | Treatment of a hemoglobinopathy |
US6069132A (en) | 1996-08-14 | 2000-05-30 | Revanker; Ganapathi R. | Phosphazole compounds |
WO1998008523A1 (en) | 1996-08-27 | 1998-03-05 | Messer Griesheim Gmbh | Hydrogenous medicament |
US20050048133A1 (en) * | 1996-09-27 | 2005-03-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US6316403B1 (en) | 1996-09-27 | 2001-11-13 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
WO1998013058A1 (en) | 1996-09-27 | 1998-04-02 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
WO1999047512A1 (en) | 1998-03-16 | 1999-09-23 | Colgene Corporation | 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
WO1999049880A1 (en) | 1998-04-01 | 1999-10-07 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
US6203991B1 (en) | 1998-08-21 | 2001-03-20 | The Regents Of The University Of Michigan | Inhibition of smooth muscle cell migration by heme oxygenase I |
US20050250688A1 (en) | 1999-04-01 | 2005-11-10 | The Trustees Of Columbia University In The City Of New York | Methods for treating an ischemic disorder and improving stroke outcome |
WO2002009731A1 (en) | 2000-07-27 | 2002-02-07 | L'air Liquide Sante (International) | Use of co for treating inflammation of upper airways or bronchi |
FR2816212A1 (en) | 2000-11-03 | 2002-05-10 | Air Liquide Sante Int | Use of carbon monoxide to treat or prevent cardiovascular inflammation e.g. ischemia, reperfusion, stenosis, restenosis, and platelet aggregation |
US20040197271A1 (en) | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
US20030068387A1 (en) * | 2001-03-30 | 2003-04-10 | Roland Buelow | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
WO2002078684A2 (en) | 2001-03-30 | 2002-10-10 | Sangstat Medical Corporation | Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
WO2002092075A2 (en) | 2001-05-15 | 2002-11-21 | Northwick Park Institute For Medical Research | Therapeutic delivery of carbon monoxide |
US20030064114A1 (en) | 2001-05-15 | 2003-04-03 | Motterlini Roberto Angelo | Therapeutic delivery of carbon monoxide |
US7045140B2 (en) | 2001-05-15 | 2006-05-16 | Hemocorm Limited | Therapeutic delivery of carbon monoxide |
US20030009127A1 (en) | 2001-05-25 | 2003-01-09 | Trescony Paul V. | Implantable medical device with controllable gaseous agent release system |
WO2003000114A2 (en) | 2001-06-21 | 2003-01-03 | Beth Israel Deaconess Medical Center | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis |
US20040067261A1 (en) | 2002-02-04 | 2004-04-08 | Werner Haas | Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof |
Non-Patent Citations (101)
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050048133A1 (en) * | 1996-09-27 | 2005-03-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US8128963B2 (en) | 1996-09-27 | 2012-03-06 | The Trustees Of Columbia University In The City Of New York | Methods for treating ischemic disorders using carbon monoxide |
US20020155166A1 (en) * | 1999-04-01 | 2002-10-24 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
US8097585B2 (en) * | 2002-04-15 | 2012-01-17 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating inflammation by administration of heme oxygenase-1 and products of heme degradation |
US20060003922A1 (en) * | 2002-04-15 | 2006-01-05 | Bach Fritz H | Spinner preparation machine and cavity resonator |
US7687079B2 (en) | 2002-04-15 | 2010-03-30 | University of Pittsburgh of the Commonwealth System of Higher Education Yale University | Methods of treating ileus |
US7981448B2 (en) | 2002-04-15 | 2011-07-19 | University Of Pittsburgh | Methods of treating necrotizing enterocolitis |
US20040005367A1 (en) * | 2002-04-15 | 2004-01-08 | Otterbein Leo E. | Methods of treating necrotizing enterocolitis |
US20030219497A1 (en) * | 2002-04-15 | 2003-11-27 | Otterbein Leo E. | Methods of treating ileus |
US20040052866A1 (en) * | 2002-05-17 | 2004-03-18 | Otterbein Leo E. | Methods of treating hepatitis |
US9522163B2 (en) | 2002-05-17 | 2016-12-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating hepatitis |
US20040258772A1 (en) * | 2002-06-05 | 2004-12-23 | Otterbein Leo E. | Methods of treating angiogenesis, tumor growth, and metastasis |
US20040131703A1 (en) * | 2002-06-21 | 2004-07-08 | Bach Fritz H. | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
US20040228930A1 (en) * | 2002-11-07 | 2004-11-18 | Billiar Timothy R. | Treatment for hemorrhagic shock |
US8927750B2 (en) | 2011-02-04 | 2015-01-06 | Universitaet Zu Koeln | Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules |
WO2013022946A1 (en) | 2011-08-09 | 2013-02-14 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating dna damage |
US9987302B2 (en) | 2011-08-09 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating DNA damage |
US9629358B2 (en) | 2013-03-15 | 2017-04-25 | Mallinckrodt Hospital Products IP Limited | Administration and monitoring of nitric oxide in ex vivo fluids |
US10667510B2 (en) | 2013-03-15 | 2020-06-02 | Mallinckrodt Hospital Products IP Limited | Administration and monitoring of nitric oxide in ex vivo fluids |
US9789133B2 (en) | 2014-04-15 | 2017-10-17 | Proterris, Inc. | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity |
US10342821B2 (en) | 2014-04-15 | 2019-07-09 | Proterris, Inc. | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity |
US11389471B2 (en) | 2014-04-15 | 2022-07-19 | Proterris Inc. | Systems and methods to improve organ or tissue function and organ or tissue transplant longevity |
WO2019040921A1 (en) * | 2017-08-25 | 2019-02-28 | Mallinckrodt Hospital Products IP Limited | Methods to improve organ viability |
CN111107742A (en) * | 2017-08-25 | 2020-05-05 | 马林克罗特医疗产品知识产权公司 | Method for improving organ viability |
EP3672403A4 (en) * | 2017-08-25 | 2021-05-19 | Mallinckrodt Hospital Products IP Limited | Methods to improve organ viability |
US11044904B2 (en) | 2017-08-25 | 2021-06-29 | Mallinckrodt Hospital Products IP Limited | Methods to improve organ viability |
US11950590B2 (en) | 2017-08-25 | 2024-04-09 | Mallinckrodt Pharmaceuticals Ireland Limited | Methods to improve organ viability |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7238469B2 (en) | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis | |
AU2002318377A1 (en) | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis | |
US7691416B2 (en) | Methods of treating vascular disease | |
US9522163B2 (en) | Methods of treating hepatitis | |
US20080171021A1 (en) | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation | |
US20140314881A1 (en) | Novel medical uses for no and no donor compounds | |
JP2005532351A (en) | Methods of treating angiogenesis, tumor growth, and metastasis | |
AU2003283982A1 (en) | Treatment for hemorrhagic shock | |
RU2376997C2 (en) | Application of carbon oxide for improvement of tissue and organ transplantation issue and apoptosis suppression | |
KR20090110362A (en) | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis | |
Sydykov | Characterization of the ROS production in ischemia/reperfusion-induced lung injury | |
Balogun | Functional role of haem oxygenase-1 (HO-1) introduction prior to hypothermic storage and reperfusion in renal tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., MASSAC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOARES, MIGUEL P.;TOBIASCH, EDDA M.;REEL/FRAME:013901/0286;SIGNING DATES FROM 20020913 TO 20021010 |
|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., MASSAC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BACH, FRITZ H.;REEL/FRAME:016499/0214 Effective date: 20040304 |
|
AS | Assignment |
Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., MASSAC Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BETH ISRAEL DEACONESS MEDICAL CENTER, INC.;REEL/FRAME:016873/0896 Effective date: 20050727 |
|
AS | Assignment |
Owner name: YALE UNIVERSITY, CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OTTERBEIN, LEO E., PH.D.;REEL/FRAME:017456/0688 Effective date: 20030213 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:YALE UNIVERSITY;REEL/FRAME:021156/0336 Effective date: 20040114 |
|
DI | Adverse decision in interference | ||
AS | Assignment |
Owner name: IKARIA HOLDINGS, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GOSE, JEANNE, DR.;REEL/FRAME:022109/0293 Effective date: 20080602 |
|
DI | Adverse decision in interference | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
DI | Adverse decision in interference | ||
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: IKARIA, INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:IKARIA HOLDINGS, INC.;REEL/FRAME:032097/0626 Effective date: 20100507 Owner name: INO THERAPEUTICS LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IKARIA, INC.;REEL/FRAME:032097/0623 Effective date: 20140129 |
|
AS | Assignment |
Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT, NEW YORK Free format text: PATENT SECURITY AGREEMENT (FIRST LIEN);ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:032426/0747 Effective date: 20140212 Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT, NEW YORK Free format text: PATENT SECURITY AGREEMENT (SECOND LIEN);ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:032426/0848 Effective date: 20140212 Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINI Free format text: PATENT SECURITY AGREEMENT (FIRST LIEN);ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:032426/0747 Effective date: 20140212 Owner name: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINI Free format text: PATENT SECURITY AGREEMENT (SECOND LIEN);ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:032426/0848 Effective date: 20140212 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: INO THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH;REEL/FRAME:035453/0487 Effective date: 20150416 Owner name: INO THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH;REEL/FRAME:035453/0513 Effective date: 20150416 |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:035454/0768 Effective date: 20150416 |
|
AS | Assignment |
Owner name: MALLINCKRODT CRITICAL CARE FINANCE INC., MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERAKOS, INC.;REEL/FRAME:038008/0824 Effective date: 20160304 Owner name: THERAKOS, INC., PENNSYLVANIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INO THERAPEUTICS LLC;REEL/FRAME:038008/0956 Effective date: 20160304 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MALLINCKRODT IP;REEL/FRAME:038009/0016 Effective date: 20160301 Owner name: MALLINCKRODT IP, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MALLINCKRODT PHARMA IP TRADING DAC;REEL/FRAME:038009/0058 Effective date: 20160301 Owner name: MALLINCKRODT PHARMA IP TRADING DAC, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MALLINCKRODT CRITICAL CARE FINANCE INC.;REEL/FRAME:038038/0009 Effective date: 20160304 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 12 |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AG Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;REEL/FRAME:049822/0674 Effective date: 20190719 Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT, NEW YORK Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;REEL/FRAME:049822/0674 Effective date: 20190719 |
|
AS | Assignment |
Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LI Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ARD IP LIMITED;MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;SPECGX LLC;AND OTHERS;REEL/FRAME:051256/0829 Effective date: 20191209 Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ARD IP LIMITED;MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED;SPECGX LLC;AND OTHERS;REEL/FRAME:051256/0829 Effective date: 20191209 |
|
AS | Assignment |
Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: OCERA THERAPEUTICS, INC., MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:060389/0839 Effective date: 20220616 Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;SPECGX LLC;AND OTHERS;REEL/FRAME:060389/0913 Effective date: 20220616 |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, NEW YORK Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;SPECGX LLC;AND OTHERS;REEL/FRAME:060434/0536 Effective date: 20220616 |
|
AS | Assignment |
Owner name: ACQUIOM AGENCY SERVICES LLC, COLORADO Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY;AND OTHERS;REEL/FRAME:065595/0376 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: VTESSE LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY, IRELAND Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 |
|
AS | Assignment |
Owner name: INO THERAPEUTICS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: IKARIA THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: THERAKOS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: ST SHARED SERVICES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: INFACARE PHARMACEUTICAL CORPORATION, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MEH, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: IMC EXPLORATION COMPANY, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT VETERINARY, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: LIEBEL-FLARSHEIM COMPANY LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: LAFAYETTE PHARMACEUTICALS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: CNS THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: LUDLOW LLC (F/K/A LUDLOW CORPORATION), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT US POOL LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT CARRIBEAN, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT FINANCE GMBH, SWITZERLAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT CB LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: MALLINCKRODT INTERNATIONAL FINANCE S.A., LUXEMBOURG Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049822, FRAME 0674;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065609/0454 Effective date: 20231114 Owner name: INO THERAPEUTICS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: IKARIA THERAPEUTICS LLC, NEW JERSEY Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: THERAKOS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: ST SHARED SERVICES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: INFACARE PHARMACEUTICAL CORPORATION, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: VTESSE LLC (F/K/A VTESSE INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED), IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MEH, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: IMC EXPLORATION COMPANY, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT VETERINARY, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: LIEBEL-FLARSHEIM COMPANY LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: LAFAYETTE PHARMACEUTICALS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: CNS THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: LUDLOW LLC (F/K/A LUDLOW CORPORATION), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MNK 2011 LLC (F/K/A MALLINCKRODT INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT US POOL LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT CARRIBEAN, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.), MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT FINANCE GMBH, SWITZERLAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT CB LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: MALLINCKRODT INTERNATIONAL FINANCE S.A., LUXEMBOURG Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 035454, FRAME 0768;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065610/0035 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: VTESSE LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: OCERA THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 |